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Abstract
Oncological diseases account for a significant portion of the burden on public healthcare systems with associated
costs driven primarily by complex and long-lasting therapies. Through the visualization of patient-specific
morphology and functional-molecular pathways, cancerous tissue can be detected and characterized non-
invasively, so as to provide referring oncologists with essential information to support therapy management
decisions. Following the onset of stand-alone anatomical and functional imaging, we witness a push towards
integrating molecular image information through various methods, including anato-metabolic imaging (e.g., PET/
CT), advanced MRI, optical or ultrasound imaging.
This perspective paper highlights a number of key technological and methodological advances in imaging
instrumentation related to anatomical, functional, molecular medicine and hybrid imaging, that is understood as
the hardware-based combination of complementary anatomical and molecular imaging. These include novel
detector technologies for ionizing radiation used in CT and nuclear medicine imaging, and novel system
developments in MRI and optical as well as opto-acoustic imaging. We will also highlight new data processing
methods for improved non-invasive tissue characterization. Following a general introduction to the role of imaging
in oncology patient management we introduce imaging methods with well-defined clinical applications and
potential for clinical translation. For each modality, we report first on the status quo and, then point to perceived
technological and methodological advances in a subsequent status go section. Considering the breadth and
dynamics of these developments, this perspective ends with a critical reflection on where the authors, with the
majority of them being imaging experts with a background in physics and engineering, believe imaging methods
will be in a few years from now.
Overall, methodological and technological medical imaging advances are geared towards increased image contrast,
the derivation of reproducible quantitative parameters, an increase in volume sensitivity and a reduction in overall
examination time. To ensure full translation to the clinic, this progress in technologies and instrumentation is
complemented by advances in relevant acquisition and image-processing protocols and improved data analysis. To
this end, we should accept diagnostic images as “data”, and – through the wider adoption of advanced analysis,
including machine learning approaches and a “big data” concept – move to the next stage of non-invasive tumour
phenotyping. The scans we will be reading in 10 years from now will likely be composed of highly diverse multi-
dimensional data from multiple sources, which mandate the use of advanced and interactive visualization and
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analysis platforms powered by Artificial Intelligence (AI) for real-time data handling by cross-specialty clinical experts
with a domain knowledge that will need to go beyond that of plain imaging.
Keywords: Oncology imaging, Instrumentation, CT, MRI, Optical, SPECT, US, Sonography, Hybrid imaging, Machine
learning
Cancer and imaging – an introduction
Cancer describes a wide range of oncological diseases
that can affect all levels of a living organism and that
have, in common, the risk of becoming systemic. Cancer
is the second leading cause of death of people with
about 17 million new cases worldwide per year. Just
under 10 million people succumb to cancer every year
[1], and one in three people is affected by cancer
throughout their lifetime. The economic impact of can-
cer – from diagnosis, treatment, patient work-up and
care, to loss of work force and other societal impacts –
is thus significant and increasing; in 2010, for example,
the worldwide direct and indirect costs were estimated
to be 1.6 trillion USD, which amounted to 230 USD per
human capita [2]. Typically, overall costs of cancer ac-
count for 10%, or more of the gross domestic product
(GDP) with marked variations across countries. Given
the severe implications of disseminated cancer, early and
accurate diagnosis is of the essence.
Imaging by means of different, and frequently comple-
mentary imaging methods provides fundamental data for
diagnosing patients, studying diseases, discovering and
monitoring new therapies, and improving human health
care. As such, the adoption rate of non-invasive, medical
imaging has been increasing continuously over the past
decades [3]. These increases can be attributed to ex-
panded demand from referring physicians and patients,
as well as from technical improvements and wider avail-
ability. More specifically, modern biomedical images re-
veal structural and functional information of subjects
in vivo (Fig. 1). At a different scale, biological micros-
copy images and molecular pathways provide further
insight into tissues and living organisms, and into pro-
cesses and structures of cellular compartments [4].
Given the different types of data generated and scale of
information, new ways of integrating and using biomed-
ical information must be found [5]. In this paper, we de-
scribe important types of biomedical imaging methods
and hypothesize on their short- to mid-term develop-
ments with a focus on oncological imaging.
Figure 2 depicts a generic view on the work-up of a
patient suspected with cancer: the patient presents with
a suspicion of cancer and is referred for an imaging
examination. Here, imaging denotes the acquisition of
non-invasive visual data of extended ranges or volumes
of the subject. Conventional imaging, as indicated in the
schematics, typically includes X-ray imaging, Computed
Tomography (CT) imaging or Ultrasound (US) or Mag-
netic Resonance Imaging (MRI), and, thus, yields ana-
tomical information, which can be employed to detect,
Fig. 1 Imaging modalities together with their colour-coded ability to depict anatomical and/or functional information. For example, X-ray
imaging is purely anatomical imaging modality, PET imaging provides functional (and molecular) data, while MRI and optical imaging are capable
of providing anatomical and functional information depending on the choice of the protocol or mode of operation
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localize and describe cancerous tissue in-vivo. However,
cancer is frequently not detectable from plain anatomical
images because of the lack of morphological alterations,
but can be identified by virtue of molecular and meta-
bolic perturbations [4].
Nuclear medicine techniques, such as Positron Emission
Tomography (PET) or Single Photon Emission Computed
Tomography (SPECT), that rely on the tracer principle,
have found an important place in the diagnostic manage-
ment of cancer [6]. The tracer principle describes the abil-
ity to label minute amounts of a biomolecule of choice
(e.g., glucose) with a radioactive isotope, which enables
tracing the labelled biomolecule (and, thus, the pathways
of the unlabeled biomolecules) by means of the emitted
radiation without disturbing normal tissue function. Like-
wise, optical imaging methods make use of fluorescent
molecular probes and ultrasound of targeted microbub-
bles to highlight signaling pathways and differential anat-
omies, respectively [7]. Nuclear medicine imaging can be
both highly-sensitive and highly-specific, but yields images
of the tracer distribution that are of lower spatial reso-
lution than that from CT or MRI, given the fundamental
differences in the detection principles of molecular and
anatomical imaging. It is this difference, and the general
challenges of localizing focal uptakes of highly-specific
tracers that have led to the development of hybrid imaging
methods, including the physical combination of PET and
CT (PET/CT), SPECT and CT (SPECT/CT), or PET and
MRI (PET/MRI) [8].
Imaging is frequently followed by bioptic sampling to
further substantiate a diagnosis (Fig. 2). Both imaging
and bioptic information are then combined to make a
clinical decision on a preferred therapeutic option, many
of which come with a serious cost to the healthcare sys-
tem. An ideal scenario for a cancer patient work-up
would include a timely and accurate diagnosis, and a full
understanding of the cancerous phenotype while per-
forming a minimal number of tests, which, in turn,
should be minimally invasive, and ultimately, lead to the
most appropriate choice of a therapy depending on the
stage and biological features of the disease (also called
“precision medicine”). Ideally, the use of confirmatory
bioptic procedures should be limited since they are
costly, time consuming, and invasive. However, biopsies
are required to determine the genetic cause of a disease
and, thus, help adjust subsequent treatment regimens.
Should biopsies be avoided in the future, then imaging
methods must be as good as deducing the phenotype of
the cancerous disease so as to planning the most effi-
cient, and personalized treatment. Here, molecular or
hybrid imaging techniques may be better placed as non-
invasive tools than other techniques.
Furthermore, the value of image parameters (also
called “biomarkers”) is often sub-optimal due to physical
and methodological limitations of the diagnostic
methods employed: anatomical imaging, for example,
may not detect or characterize a lesion because it is not
manifested as a morphological alteration even though
Fig. 2 Schematics of a generic management of cancer patients: frequently, a conventional imaging exam (X-ray, CT, and alike) is performed
before an additional, combined imaging exam (e.g., PET/CT) is ordered. Imaging may be followed by a biopsy procedure or genomic analysis to
further differentiate the disease. A report is created and the oncologist decides on the choice of an appropriate therapy. It is evident that
imaging is the gatekeeper to important clinical decision making and therapy deliveries. This cycle can be re-iterated multiple times during patient
management and follow-up. The actual implementation of this patient management chart will be affected by the availability of imaging
modalities, reimbursement guidelines and other locally variant healthcare regulations
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cancerous tissue is present. Molecular imaging, on the
other hand, may miss even hypermetabolic lesions because
they are too small to be detected in view of the partial vol-
ume effects (PVE) arising from the limited detector reso-
lution [9] or because the lesion resides in an area of the
body that is affected by motion (e.g., respiration), which
leads to a smearing of the tracer uptake and a resulting
contrast that is insufficient to delineate the lesion. Add-
itionally, high uptake in adjacent tissues can diminish con-
trast and, therefore, sensitivity for lesion detection. The
strengths and weaknesses of each imaging modality, with
regards to depicting anato-metabolic details or plain lesion
detection will play into the adoption of these modalities as
standards of care along the cancer management pathway
(Fig. 2). Supplementary Figure 1 further details the use of
all seven key imaging modalities presented here for diagno-
sis, staging, restaging, and follow-up.
However, imaging technologies have improved greatly
over the years. This is through the use of improved de-
tector elements or the adoption of model-based image re-
construction methods for increased lesion-to-background
contrast in the images of the tracer distribution. In the
early years of imaging innovation, much effort went into
the design and optimization of techniques that increased
the sensitivity of an imaging system, while only recently,
attention has shifted to optimizing imaging technologies
to a higher specificity as well, so as to provide means to
non-invasively assess the phenotype of tumours that
present in most cases as heterogenous masses with intra-
and inter-lesion variations in molecular and signaling
pathways [10]. Thus, the role of imaging has remained
ever so important but the demands on the imaging tech-
nologies have become more complex. The objective of this
perspective is to highlight key developments of imaging
methods used frequently in cancer patient management
(Fig. 1) and to carve out potential areas of improvement
that are foreseen in the near future.
Positron Emission Tomography (PET) imaging and
instrumentation trends
PET is a non-invasive imaging technique that provides
visual and quantitative information on molecular path-
ways. Imaging is performed post injection of a radio-
tracer, which – in the case of PET – is a biomolecule
labelled with a neutron-deficient radioisotope [11]. Dur-
ing the subsequent positron decay (β+) a proton is con-
verted to a neutron thereby releasing a positron. The
β + travels a short distance - termed the positron range -
before it annihilates with an electron from the surround-
ing tissue so as to form two annihilation photons of 511
keV each that travel in nearly opposite directions. The
spatio-temporal distribution as well as the absolute con-
centration of the tracer can be determined through the
detection and reconstruction of annihilation events
(Fig. 3). Today, PET imaging has been partnered with
CT and MR imaging, namely as PET/CT and PET/MR
hybrid imaging systems to provide more relevant infor-
mation in routine clinical practice [12].
Status quo
With more than 6000 PET/CT systems and approxi-
mately 250 PET/MRI systems operational worldwide,
the key application of PET imaging is for oncological in-
dications [13]. Here, [18F]FDG, an [18F]-labelled glucose
analogue, is the tracer-of-choice to assess the increased
glucose turnover in cancerous tissues compared to nor-
mal tissue (Warburg effect). The key challenges when
diagnosing cancer by means of PET are related to cancer
biology and the actual ability to visually circumscribe the
cancerous lesion using reconstructed PET images. Can-
cer biology is addressed by the a priori choice of a suit-
able tracer molecule to probe the existence of a
suspected disease and to further phenotype it. The avail-
ability of molecular probes and the choice of the most
appropriate tracer will be the focus of a companion con-
tribution to this series.
Image resolution, which drives lesion detection, is de-
termined by the size of the imaging detector elements,
which is on the order of 3 mm in clinical PET systems
[14]. The resulting imaging resolution is somewhat lower
due to detrimental effects from positron range effects,
which vary depending on the energy of the positron
emitted, detector penetration and depth-of-interaction
(DOI). It can also be influenced by image reconstruction
and respiratory physiological movement during acqui-
sition. Despite the final image resolution of PET be-
ing lower than that of MR or CT, lesions with a
diameter less than the theoretical image resolution
can still be detected if their contrast is sufficiently
high; this is frequently seen in applications of [124I]-
iodide and [68Ga]-somatostatin and -PSMA ligands
due to the combination of high binding affinity and
low background uptake [15]. In addition to the detri-
mental effects of limited spatial resolution (image
blurring, partial volume effects), attenuation and scat-
ter of the annihilation photons cause visual distortion,
bias and lower contrast as well as limited count-rates,
all of which contribute to increased image noise and
reduced image contrast (Suppl Figure 2) [16–23].
The standard PET detector is composed of the scintil-
lation material that stops/detects the annihilation pho-
tons and an electronic device – a photomultiplier tube
(PMT) – coupled to the end of the detector material,
that, in turn, transforms the detected scintillation pho-
ton into an electrical signal, which typically involves sig-
nal amplification and processing. The ideal PET
scintillator material has a high stopping power – suffi-
cient to attenuate the 511 keV annihilation photons, high
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scintillation light output – to facilitate accurate detection
of the annihilation photons, fast decay time - to
minimize deadtime, high energy resolution - to better
discriminate against scattered photons, and low cost
(Suppl Table 1) [14].
Recently, digital PMT – better known as silicon PMT
(SiPM) – have been introduced as a replacement to
analogue PMTs. SiPMs function as an ON/OFF switch,
such that if scintillation light hits the SiPM an electrical
pulse with sufficient amplitude is generated. With SiPM
the limitations of light absorption and conversion as well
as spatial resolution are drastically reduced when com-
pared to an analogue PMT. Furthermore, their small
and compact form factor and their magnetic-
susceptibility tolerance make them ideal devices for use
in PET/MR systems compared to their PMT counter-
parts, which are not MR-compliant.
The introduction of LSO- and LYSO-based detectors
with their characteristic fast scintillation light decay time
(Suppl Table 1) have enabled a form of PET image ac-
quisition and reconstruction known as time-of-flight
(ToF) imaging [24]. With ToF imaging, information
about the minute difference in arrival time of the annihi-
lation photons at opposing detectors is captured. This
knowledge is subsequently used during image recon-
struction to more precisely inform on where the annihi-
lation event occurred within the PET field-of-view
(FOV) as compared to conventional PET imaging. The
knowledge about the arrival time has been shown to im-
prove the resultant signal-to-noise ratio (SNR) of recon-
structed PET images [14]. For example, a 300 ps timing
resolution improves the SNR of ToF images by about
30% when compared to non-ToF images. Furthermore,
larger patients benefit more from ToF imaging than
smaller subjects [25].
Following the detection of the annihilation photons,
corrections for self-absorption and scatter must be ap-
plied prior to image reconstruction. In PET/CT, the use
of CT has been utilized for the purpose of CT-based at-
tenuation correction (CT-AC) and scatter correction
[26]. Studies have demonstrated a diagnostic benefit
when performing the CT portion of the PET/CT at a
radiologically-equivalent quality [27]. Some users advo-
cate – with promising results - an adapted, mixed-phase
contrast administration that can be used for both diag-
nostic [28] and CT-AC purpose [29].
A key challenge to high-quality and quantitative PET is
physiological motion, including respiratory and cardiac
motion, that may cause noticeable mismatches between
the PET and CT images and blurring due of the PET im-
ages. Conspicuity of tracer uptake in lesions that are lo-
cated in regions affected by physiological motion can be
reduced through the use of gating or more complex mo-
tion compensation techniques. Gating describes the parti-
tioning of a standard list-mode stream of emission data
acquired during a PET scan by means of external or data-
driven trigger schemes [30]. Several techniques have been
developed to address these distortions, such as 4D PET/
CT [31] and quiescent phase/amplitude gating [32] with
various levels of success and limited adoption into routine
clinical work given the complexity of the workflows
(Fig. 4). Motion compensation benefits from the hardware
combination of PET and MRI, since a variety of MR se-
quences can be exploited to estimate motion vector fields
without the requirement for ancillary markers or in-
creased radiation burden [33, 34].
Fig. 3 Positron Emission Tomography (PET) imaging: a neutron-deficient, radioisotope (positron emitter) is used to label a biomolecule of choice
(here: glucose; Tracer,) which is injected into the patient. The resulting annihilation radiation is detected in a PET system, the data are sorted into
sinograms and stored in sonograms prior to image reconstruction. In case, post-acquisition scatter and attenuation correction is performed.,
tracer uptake in the PET images can be quantified. Materials courtesy of David W Townsend, Singapore
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Image reconstruction in PET has evolved from the ori-
ginal 2D analytic techniques, such as filtered back pro-
jection (FBP) to the more recent 3D iterative
reconstruction (IR) techniques, such as ordered subset
expectation maximization (OSEM) (Fig. 5). Iterative re-
construction techniques have the added advantage of
more accurately modelling the physics of the imaging
process compared to analytical methods but they are
also computationally more expensive and require a rela-
tively longer time to reach convergence (i.e. solution).
Additionally, when they reach convergence, the resultant
images are characterized by high noise. In an effort to
overcome this challenge, recent advances in this area
have introduced regularized reconstruction approaches,
which have the ability to minimize the noise while
reaching convergence.
Lesions with comparatively low contrast to the sur-
rounding tissue can be hard to detect, particularly in
noisy imaging conditions originating, for example, from
very short scan times, very low amounts of tracer activity
injected or from scanning obese patients, which in-
creases the scatter fraction. Thanks to the use of
Fig. 4 [18F]-FDG PET images of a 60-y/o male (362 MBq, BMI = 28) with colorectal cancer. Images show lewsions in the liver and right lower lung
that are affected by motion-induced blurring. Left: without motion compensation, middle: with amplitude motion compensation that utilizes 35%
of the acquired data resulting in noisy images but reduced motion artifact, and right: with amplitude motion compensation that utilizes all the
acquired data resulting in lower image noise and motion artifact
Fig. 5 [18F]-FDG PET images of a 71-y/o female (324 MBq, BMI 22) with endometrial adenocarcinoma post hysterectomy, bilateral oophorectomy
and lymph node dissection. Images show the differences in quality when using FBP reconstruction (left), iterative reconstruction (middle), and
regularized reconstruction (right)
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advanced scanner designs that allow for larger coverage
of axial FOVs, new PET/CT systems permit shorter ac-
quisition times, lower administered radiotracer amount,
and easily, repeated imaging of any region of the body.
These repeated whole-body PET scans can then be used
to derive radiotracer uptake rate constants (Ki-values)
and, thus, estimate parametric images in addition to
plain standardized uptake value (SUV) images (Fig. 6).
In summary, PET imaging today comes in flavours of
combined PET/CT and PET/MRI with both design con-
cepts being geared towards whole-body oncology im-
aging and less so full quantification. This visualization-
driven approach is complemented with user software
that generally limits data handling to 3D slicing of re-




Most state-of-the art PET/CT systems use LSO or LYSO
detector materials coupled to SiPM, and unless other,
faster scintillation type detectors can be marketed, these
will remain the material of choice for the years to come.
Technological progress is expected in the advances of
SiPM technologies, so as to making these amplifiers
smaller and more robust. Furthermore, their small size
should aid in the positional accuracy of the detected an-
nihilation photons thereby improving overall image reso-
lution and further reducing partial volume effects.
Time-of-flight PET
Current timing resolution of PET systems is on the
order of 250-500 ps. If the timing resolution improves by
a factor of 10 (25-50 ps) then there will be no immediate
need for image reconstruction since the image can be
directly generated as the data are acquired. Recently, an
initiative was launched by a CERN-linked consortium to
push for a 10 ps timing resolution in PET in order to
bring together enthusiastic stakeholders to advance on
this particular technological challenge for a wider adop-
tion of PET imaging [35]. To meet this challenge, detector
materials that combine the upsides of LSO or LYSO but
with even faster timing resolution, have to be found and
manufactured in scale. Another benefit of a faster detec-
tion system is better count-rate performance with lower
dead-time effects over extended ranges of radioactivity
levels, as in situations where the administered radiophar-
maceutical accumulates in high concentrations.
Attenuation and scatter correction
It appears unlikely that CT transmission scans will be
avoided in PET/CT in the future, unless techniques such
as maximum likelihood attenuation and activity (MLAA)
[36, 37], which can approximate both the attenuation
map and the resultant image for the acquired data, or
Machine and Deep learning-based AC methods for PET
imaging applications are developed. However, little data
is available as to the robustness of these approaches and
their performance in the presence of varying tracer dis-
tributions, morphological alterations or high-density
implants.
Motion compensation
Data-driven gating (DDG) techniques have been intro-
duced to address patient motion induced image blur
[38]. DDG benefits from using fast PET detectors that
yield a high SNR to allow the extraction of the motion
waveform from the background noise. It is anticipated
Fig. 6 State-of-the-art PET/CT acquisitions allow for the repeated sweeps of extended axial imaging ranges during the emission scan following
the injection of the tracer. These data can be reconstructed in contiguous frames (see Frame 1-8 as an example) that are used to extract time-
activity curves of tissues and organs. This information, in turn, can be used to derive parametric images (e.g., ki and distribution volume, DV)
beyond static images that yield SUV quantification only. It is assumed that parametric image information supports more accurate diagnosis in the
future. (Figure made with contributions from Rahmim (2019) and Keio Gijyuku University Hospital, Japan)
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that with the elimination of external devices to record
the motion cycle, the motion compensation workflows
will become much easier to use and will be adopted rou-
tinely in the PET clinic. In return, PET image quantifica-
tion will be more accurate and patient management will
be more precise [39].
Image reconstruction
Assuming the 10 ps challenge will not be answered in
the next few years, iterative reconstruction (IR) will pre-
vail (Fig. 5b). IR methods will be improved with more
advanced system models that describe various aspects of
the hardware and the subjects (motion, tracer distribu-
tion etc) more accurately (Fig. 5c). For example, CT at-
tenuation maps might be compromised by metal
artefacts, truncation, and contrast media; or in the case
of PET/MR attenuation maps may not be available
altogether since MR images do not represent tissue at-
tenuation. In this regard, new reconstruction algorithms,
such as MLAA and artificial intelligence along with ma-
chine learning approaches that use deep learning algo-
rithms hold a big promise in addressing these challenges
[40–42]. The performance of these techniques is cur-
rently being evaluated under various clinical conditions
such as low count-density (shorter scan times, low activ-
ity) and varying radiopharmaceutical biodistributions.
New system design concepts
Traditionally, PET systems have been designed as cylin-
drical structures with detectors dotting the circumfer-
ence of these structures and oriented towards the
central axis of the cylinder. More recently, systems with
longer axial lengths have been introduced. By placing
detector modules abutting next to one another along the
axial extent of the scanner, lengths of 20 cm, 25 cm and
26 cm have been achieved on commercial systems from
GEHC and Siemens Healthineers respectively, with one
manufacturer (United Imaging) achieving 194 cm [43].
This increase in axial extent has two key advantages.
First, it increases sensitivity, which can be translated into
higher image quality or traded for a reduced injected ac-
tivity, and, second, it facilitates increased patient
throughput by reducing acquisition time. A total-body
PET/CT scan can then be performed in one minute, or
less and with a significantly reduced amount of adminis-
tered radiotracer, which consequently reduces patient
radiation exposure, thereby potentially transforming the
use of PET imaging from a diagnostic tool to a screening
tool. Other advantages of total-body PET with longer
axial extents include the ability to perform dynamic im-
aging of multiple organs simultaneously, which enables
the study of the bio-distribution and pharmacokinetics
of new radiopharmaceuticals and disease states with im-
ages representing true biological parameters, such as
tracer uptake rate constants (Ki), blood flow, or receptor
density rather than just semi-quantitative values, such as
standardized uptake values (SUV) (Fig. 6).
PET/MR systems will continue to evolve albeit slowly
when compared to PET/CT with improvements in at-
tenuation correction, truncation, and image uniformity
in organ-specific or whole-body applications. Their
adoption into routine clinical care will primarily depend
on the identification of clinical applications that leverage
the advantages of MR (compared to CT) while comple-
menting the diagnostic information gained from PET
[44, 45].
In summary, PET imaging systems will come primar-
ily in combinations with CT for whole-body oncology
applications, unless, key drivers for the adoption of fully-
integrated PET/MRI are found, in which case relatively
more PET/MRI systems could be installed. PET detector
elements can now be manufactured with very fast scin-
tillation materials and produced in modules fit for use in
PET/CT and PET/MRI combinations. These modules,
when designed with SiPM, should help improve spatial
resolution and reduce partial volume effects. The use of
ToF and advanced image reconstruction algorithms will
create flexibility in imaging protocol designs and help
push the image quality even in low-count situations,
which helps in signifying even early time-point measure-
ments shortly after tracer injection, and with parametric
imaging. Motion compensation will likely become key
for the advancement of the methodology, which, if re-
solved, will open PET for a wider range of applications
and help push it into PET-guided therapy planning. In
short, the authors hypothesize a primary push for sensi-
tivity and full quantification, which is further supported
by fast and higher-resolution measurements (Table 1).
SPECT imaging and instrumentation trends
As with PET, SPECT is a non-invasive molecular im-
aging method that generates tomographic images of
functional and metabolic pathways in the body. Unlike
in PET, SPECT is based on the use of radiotracers that
are labelled with radioisotopes that decay via the emis-
sion of single or multiple photons of discrete energies.
Given the lack of annihilation effects, SPECT relies on
the use of physical collimators to generate projection
data for localization of the SPECT tracer. SPECT has
only recently been made quantitative through the adop-
tion of correction and image reconstruction approaches
[46].
Status quo
The availability of SPECT and its ability to image a
range of metabolic signals has made it commonplace in
oncology imaging for both diagnosis and disease moni-
toring. From the identification of bone metastases [47]
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to the assessment of malignant thyroid conditions [48],
SPECT is a common feature of oncology imaging. More
recently, with the growth of theranostics [49], radio-
nuclide therapies, and image-based dosimetry associated
with therapies, there has been renewed interest in
SPECT imaging technology.
SPECT systems are typically based on a pair of large
(540mm× 400mm) energy selective scintillation detector
arrays, with positional information derived from the use of
lead or tungsten constructed collimators and the Anger
principle [4]. The technology is well established and has
changed little since its inception in 1956. Nevertheless,
driven by the need for more compact and innovative de-
signs initially for cardiac SPECT [50], but more recently
for breast [51] and general oncology imaging [52], semi-
conductor detectors have been introduced as an alterna-
tive to traditional scintillation detector systems. The most
common semiconductor material used for SPECT is Cad-
mium Zinc Telluride (CZT) [53]. In addition to its com-
pactness and with its direct translation of gamma photon
to signal, CZT detectors offer superior energy resolution
compared to traditional gamma cameras [54]. This trans-
lates into improved scatter rejection, in addition to sensi-
tivity and contrast gains [55]. CZT is also incorporated
into SPECT systems as individual pixelated detectors,
which allows the system to work at higher count rates
than traditional gamma camera designs [53].
The introduction and development of dual-modality
SPECT/CT systems has been another step change in
SPECT [56]. Transmission imaging in SPECT was originally
introduced to correct for photon attenuation in cardiac
studies, but was soon superseded by much quicker SPECT/
CT systems. In addition to attenuation correction from
SPECT/CT systems, the advantages of having localization
and other complementary CT information superimposed
with SPECT was quickly realized [56–58]. Co-localisation
has been particularly beneficial for oncological applications
of SPECT, where for example, CT can help determine
whether bone lesions are cancerous or degenerative in na-
ture, and also with radiopharmaceuticals such as mIBG,
where the anatomical information available in the SPECT
image can be limited (Fig. 7).
In parallel to the growth of CT-based attenuation correc-
tion [59], iterative reconstruction algorithms have replaced
traditional FBP reconstruction [60]. One advantage of itera-
tive reconstruction is the ability to integrate corrections into
the image reconstruction, which provides superior solutions
than correction pre or post reconstruction. This approach of
integrating corrections into the reconstruction process started
with attenuation and scatter correction, but has been devel-
oped further by the introduction of resolution modelling into
the reconstructions system model [61]. The noise handling
nature of resolution modelling is revolutionizing SPECT ac-
quisition protocols because it can provide significant (~ 60%)
Table 1 Progress indicators of methodological and commercial efforts towards improving key imaging technologies and widening
their applications in clinical cancer care. System costs relate to costs of manufacturing a next-generation imaging system.
Reproducibility relate to efforts made towards increasing reported accuracy of imaging results from the same system generation and
across different platforms. Absolute quantification stands for means to extract absolute numeric values from image-based
measurements. Radiation exposure describes exposure of subjects to ionizing radiation (or other means of energy deposit, such as in
case of MRI). Examination time describes duration that subjects need to remain motionless in an imaging platform for the
acquisition to take place. Spatial resolution is the measured resolution of the images. System sensitivity relates to both volumetric
sensitivity of an imaging system and diagnostic sensitivity through the use of alternative tracer and contrast applications. The
direction of the progress indicators, as relative metrics, corresponds to the consensus of the authors regarding the progress being
made in any of these efforts within the next 5 years, or so
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reduction in acquisition time for the same level of image
quality provided by traditional reconstruction methods [62].
This is a great benefit for some oncology-based SPECT stud-
ies where acquisition times can be 30min, or longer. Alter-
natively, resolution modelling can be used to improve image
quality for the same acquisition time as is used traditionally.
In summary, SPECT with its wide range of available
radiopharmaceuticals, its low cost and ready availability
provides oncologists with images of metabolic disease
for diagnosis and disease monitoring. Recently, the tech-
nology has also seen growth driven by theranostic appli-
cations. The introduction of dual-modality SPECT/CT
has helped overcome some the challenges of SPECT-
only image interpretation, and developments in detector
technology and image reconstruction have helped im-
prove image quality. Nonetheless, imaging times are still
long and fully-quantitative SPECT imaging is challen-
ging – unlike in PET where it is commonplace.
Status go
Hardware
One of the major drawbacks in current SPECT technol-
ogy is its limited sensitivity, which results in much lon-
ger examination times compared to PET. As such, scan
times of 40 min to 70min are typical if multiple SPECT
acquisitions are required to image the area of interest.
Therefore, for SPECT to prosper, more rapid scan
technology is required. A promising method that has
been adopted in cardiac SPECT, but which has not yet
translated to oncology SPECT yet is the use of very
high-sensitivity collimators [54]. One of the key limita-
tions of such collimators is the compromise of spatial
resolution. However, if septal penetration is adequately
controlled, there is the opportunity to use resolution
modelling techniques to recover much of the lost
resolution.
A second method of increasing the sensitivity of
SPECT systems is to improve the detector geometry by
considering alternative designs to the traditional two ro-
tating planar detector arrangement. The return of 3, 4,
or more rotating detectors can bring significant gains,
but this solution is problematic because of the degraded
spatial resolution seen with traditional parallel hole colli-
mators at the distances necessary to accommodate the
detectors. However, the growing availability of resolution
modelling within the image reconstruction will allow the
re-adoption of this design concept for SPECT. Complex
collimator designs, such as multiple pin-hole [52] and
slit-slat collimators [63], could also bring sensitivity
gains while maintaining acceptable spatial resolution.
Such efforts could be matched with improvements to in-
trinsic spatial resolution and semi-conductor readout
[64]. While complex collimator designs are an area of
interest, whether this technology can be extended to
Fig. 7 Iodine-123 MIBG image of a NET metastasis shown with (a) SPECT and (b) SPECT/CT. SPECT only images of the metastasis do not provide
anatomical information, while the SPECT/CT image provides both localization and complementary CT information
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larger fields-of-view rather than small field-of-view ap-
plication, such as in the brain, is to be determined.
Detectors
Semiconductor detector technology based on, for ex-
ample CZT, is also moving into oncological SPECT. Ini-
tial models have been based on traditional dual detector
design with the improved energy resolution offering
some clinical advantages [65]. More recently ring de-
tector systems have been produced, which again improve
the geometric and overall sensitivity of SPECT systems,
while maintaining spatial resolution by using dynamic
detector motions [66]. There is no doubt that this ring
detector technology will bring benefit to organ-specific
imaging, such as the heart, where dynamic tomographic
imaging has already shown to be beneficial, and the
brain where dynamic imaging and motion correction
could offer significant advantages. The ability to easily
perform whole-body tomography for oncology applica-
tions, such as bone SPECT, and mIBG SPECT will bene-
fit staging and disease progression applications in much
the same was as seen in PET. Large volume SPECT will
also bring benefits with dosimetry applications, by en-
suring that dosimetry of tumours and organ at risk can
be performed in a timely manner. However, a disadvan-
tage of current semiconductor detectors is the usable en-
ergy range, which is typically below 200 keV. While
acceptable for imaging with Technetium-99m and
Iodine-123 radiopharmaceuticals, this threshold is not
compatible with common theranostic radionuclides. For
example, the threshold sits below the preferred 208 keV
imaging window of Lutetium-177 [67], and well below
the upper 364 keV energy window of Iodine-131. To
allow faster SPECT acquisitions using a ring detector,
semiconductors optimal for these higher energies may
be required, or possibly using scintillation crystals with
traditional or solid-state readout [64, 68].
Hybrid SPECT
Another area where we may see hardware changes in
the future is in alternative hybrid SPECT imaging. While
SPECT/CT already exists, there are also developments
in SPECT/MR [69]. In addition to MR providing much
better soft tissue contrast for SPECT localization than is
available with CT, as with PET/MR there are also oppor-
tunities to use MR information to manage patient mo-
tion [70], improve image reconstruction [71], and to
delineate areas of interest, which in turn could be used
to perform partial volume correction of the emisison
data [72].
Data processing
The development of contemporary correction and image
reconstruction algorithms has brought with it the ability
to use SPECT as a quantitative imaging modality in
much the same way as PET [73]. Measurement of in-
vivo activity concentrations or standardized uptake
values (SUV) are now possible and may become the
norm in future SPECT imaging (Fig. 8). Indeed, as with
PET, by incorporating segmentation algorithms, mea-
surements will be developed further to help derive meta-
bolic tumour volumes and total tumour burden to better
characterize the overall disease status [74]. The basis of
this technology already exists [75], and applications of
the technology are being investigated for both cross-
sectional diagnosis prognosis and staging, as well as lon-
gitudinal treatment response and disease progression in-
dications [46].
Reconstruction and corrections
Although CT-AC may become the norm with very few
SPECT-only studies performed, there will be a drive to
reduce CT radiation exposure by the use of improved it-
erative CT reconstruction and artificial intelligence algo-
rithms [76–78]. Indeed, similar techniques will also be
applied in SPECT, where available count statistics in on-
cology imaging are often limited, and there is an inability
to extend already long scan times. Improved iterative re-
construction models using penalized likelihood [79, 80]
and improved resolution modelling will help, particularly
if they overcome overshoot ‘Gibbs’ artefacts [81]. Add-
itionally, developments with scatter correction algo-
rithms will help move the technology from subtractive
techniques, which are inexact and increase image noise
[82] compared to those incorporated into image recon-
struction [60], which do not increase image noise. Artifi-
cial intelligence algorithms are already being developed
that can improve the levels of noise seen with low count
statistic studies, and it is envisaged that in the next 5-10
years such algorithms will make issues from low photon
flux imaging less problematic [83].
An issue that can come from the necessary long acqui-
sition times of SPECT is that of patient motion. In
SPECT, spatial resolution is typically between 8 mm and
12mm, so small levels of patient motion are not prob-
lematic. However, larger levels of motion will degrade
image quality, and frequently require the patient to be
rescanned. To overcome these issues, motion detection
and improved motion correction software is being devel-
oped, which will help both identify motion and correct
data where possible, while also alerting the technologist
when the data is unusable [84]. It is also envisaged that
that there will be significant development in future years
in the routine application of Monte Carlo based image
reconstruction techniques [75]. Currently algorithms are
very slow and mostly used in research labs, but there is
huge potential in this form of reconstruction.
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Theranostics
While SPECT already has an important role in theranostics,
there has been a recent surge of new theranostic applica-
tions using Lutetium-177 labelled peptides in neuroendo-
crine tumours, and PSMA in prostate cancer [85–89] with
many other therapeutic areas in development by commer-
cial partners [90]. Key to making the best use of this tech-
nology is the need to understand the radiation dose given
to various tumour targets and organs at risk. Quantification
of radiopharmaceutical uptake together with accurate seg-
mentation of tumours and organs of interest are central to
the derivation of accumulated activity curves required for
radiation dosimetry. Currently, performing this work is
challenging, and often requires additional imaging, charac-
terisation, and home-grown image processing algorithms
[91]. Supported by tools to assist in the calibration and
standardisation of quantitative SPECT systems, the practice
of dosimetry in molecular radiotherapy will become wide-
spread, supporting the vision of personalised precision
medicine with theranostics.
Radiopharmaceuticals
A more detailed synopsis of radiopharmaceuticals will
be given in an accompanying paper by Blower and col-
leagues. Nevertheless, with the penetration of SPECT in
the market and the wide availability of SPECT radionu-
clides, there is the possibility of moving PET radiophar-
maceuticals to SPECT - as seen with Technetium-99 m
labelled TOC, PSMA and glucose analogues [86, 92, 93].
Clearly, this is an opportunity for low- and middle-
income nations where PET and cyclotron technology
may not be readily available, while for high-income
countries it may depend on whether the sensitivity and
spatial resolution limitations of current SPECT technol-
ogy can be overcome.
In summary, SPECT hardware designs will evolve rap-
idly, which together with developments with collimation
and image reconstruction will improve the sensitivity of
SPECT systems and reduce examination time (Table 1).
There is also the potential for improvements in sensitiv-
ity and spatial resolution, which will result in SPECT im-
aging with better quality than we have today. While
technological changes will have an impact, it is with the
modality becoming truly quantitative that the use of
SPECT that will grow. The current growth trajectory of
theranostics and the ability to quantify SPECT data in
terms of SUV will lead to a greater demand in SPECT
for both radiation dose assessment, and the ability to
monitor treatment response. Beyond theranostics, quan-
titative SUV SPECT will help in the interpretation of
SPECT data and will lead to more precise diagnosis
using the technology.
Computed Tomography (CT) imaging and
instrumentation trends
Computed tomography (CT) is an anatomical imaging
method. Here, a narrow beam of X-rays is directed to
the subject and quickly rotated around the body, thereby
producing transmission signals. These signals are proc-
essed and reconstructed to form cross-sectional images
of the subject under investigation. CT is a tomographic
imaging method that generates contiguous axial images,
which can be digitally stacked to form 3-dimensional,
high-resolution images of the investigated area. Onco-
logic diseases can be depicted through alterations of
standard anatomy or alterations of dynamic processes,
such as restricted intravenous contrast enhancement.
Status quo
X-ray transmission
Diagnostic CT imaging is based on the measurement of
X-ray absorption from a large number of different view
angles across the patient. State-of-the-art CT systems
offer a sub-second rotation time and are capable of ac-
quiring multiple slices simultaneously, thereby covering
a longitudinal range of 2 cm to 16 cm during a single ro-
tation. The most dominant scan mode in CT is the
spiral scan mode, which is a continuous data acquisition
Fig. 8 Contemporary SPECT software allows the direct derivation of voxel values and regions in terms of activity concentration or SUV as shown
in this post Iodine-131 ablation SPECT/CT scan. Using this quantitative information (e.g., in the spinal lesion), it is possible to track the metabolic
responses to therapeutic interventions over time
Beyer et al. Cancer Imaging           (2020) 20:38 Page 12 of 38
combining a continuous gantry rotation with a simultan-
eous translation of the patient through the gantry [94].
The trajectory of the X-ray source relative to the patient
is a spiral, or helical trajectory. Spiral acquisitions yield
the lowest possible scan times at the highest possible
image quality, whereby the latter is due to the high sym-
metry of the spiral trajectory. In general, scan times
range from far below 1 s to several seconds. Nearly all
scans can be conducted within a single breathhold,
thereby avoiding respiratory motion artefacts.
Quantification
CT systems offer an isotropic spatial resolution of about
0.5 mm and, therefore, are best suited for anatomical im-
aging. The physical property that is displayed in CT is
the distribution of the linear attenuation coefficients. For
convenience, the values are linearly transformed to be-
come integer-valued Hounsfield units (HU) in a way
such that air corresponds to − 1000 HU, water to 0 HU,
and soft tissue and fat to about 50 HU, and -70 HU, re-
spectively. However, tissue differentiation by means of
HU alone remains challenging, particularly for a range
of soft tissues; while soft tissues exhibit similar X-ray at-
tenuation properties, their difference is noticeable more
clearly on MR images. Therefore, most CT scans in
oncological imaging require the administration of an io-
dinated contrast agent to achieve sufficient image con-
trast between the vessels, perfused organs and tumours
relative to the surrounding soft tissue and fat. The con-
trast injection is typically synchronized with the acquisi-
tion of the CT scan to ensure sufficient contrast in the
organ of interest during the short time of scanning.
Functional CT
Functional properties can be assessed with CT by per-
forming dynamic perfusion scans. During perfusion pro-
tocols, a 4D acquisition is performed by repeatedly
imaging the same body region in time lapses of 3 s to 5 s
for about 30 s post administration of the contrast agent.
Using the so-called “time attenuation curve”, important
hemodynamic parameters can be derived, such as the
blood flow, the blood volume, or the permeability sur-
face area product. Such functional parameters have been
shown to correlate with histopathology and therapy re-
sponse [95–97].
Ionizing radiation
Despite the lack of solid arguments for a linear no
threshold (LNT) model, fears associated with radiation-
induced risks have led to a wide number of efforts to re-
duce the dose in CT. These include the introduction of
tube current modulation, automatic exposure control,
automatic tube voltage selection, more powerful X-ray
tubes that allow for thicker pre-filtration, highly-
integrated detectors with less internal noise, multi-
dimensional adaptive raw data filtering, as well as itera-
tive image reconstruction algorithms [98]. These tech-
niques make more efficient use of the X-ray dose and
help reduce the X-ray dose while preserving image qual-
ity. Alternatively, such methods can also be used to im-
prove the image quality without increasing the patient
dose. The latter may be of importance for oncological
imaging where frequently subtle contrast changes in
small lesions need to be detected, and where patients
may undergo a large number of follow-up scans. The
need for dose-conscious CT imaging is typically amplified
when scanning young patients.
Detectors
Suppl. Table 2 lists important properties of state-of-the-
art CT systems. For example, maximum tube power at
low tube voltages helps lower patient exposure or boost
image quality of contrast-enhanced scans, since the iod-
ine in contrast agents exhibits a k-edge at low energies.
Most CT vendors provide the possibility to reconstruct
the images at grids larger than 512 by 512 pixels, so as
to use the full spatial resolution capabilities for large
field-of-view reconstructions, which helps improve sensi-
tivity in lung imaging or imaging bone metastases.
Dual-energy CT (DECT)
DECT exploits differences in the energy dependency of
the attenuation coefficients and thus allows to selectively
display materials that might appear at the same CT value
in single-energy CT. DECT is can be realized by includ-
ing a dual-source CT, a CT with fast tube voltage
switching, a CT equipped with a sandwich or dual-layer
detector, or a CT with different prefiltration on different
parts of the detector array [99]. Approaches that com-
bine two separate CT scans are also available, but suffer
from motion in-between the scans. Applications of
DECT include the selective display of iodine and bone,
the characterization of kidney stones, the reduction of
artefacts and the quantification of materials (Fig. 9). Ad-
vantages of DECT for oncological imaging have been re-
ported for tumour detection and lesion characterization
[100] and for surrogates of perfusion measurements
[101, 102]. Well-designed scan protocols help distribute
the X-ray dose across the two X-ray spectra, such that
the total dose remains similar to that of a single energy
CT [103, 104].
Metal artifact correction (MAR)
Metal artefacts are the most dominating type of artefacts
in CT. In many cases, metal artefacts prevent accurate
diagnosis of lesions that are close to or in-between metal
objects. Moreover, the artefacts degrade the attenuation
correction needed for PET imaging [105]. Metal artefacts
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Fig. 9 Patient with HCC before and after hadron therapy. DECT helps delineate iodine uptake within the tumour and the recurrent lesions. The
contrast accumulations (gray arrows) in the irradiation field (blue arrow) can only be deduced from the iodine map, thus, improving
differentiation of HCC and surrounding healthy liver. Data courtesy of the Division of Radiology of the German Cancer Research Center (DKFZ)
Fig. 10 Conventional energy integrating (EI) detectors convert the X-rays into an electric signal indirectly (left). Future photon counting (PC)
detectors convert each X-ray photon into an electric peak directly (right). The peak of the PC detector is short enough in time to permit counting
single photons. The peak height gives information about their energy. To minimize pile up the PC detector pixels are much smaller than the
EI pixels
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are mainly caused by the strong beam-hardening of
dense objects, related to the strong attenuation of metal.
Due to the corruption of the projection data behind the
metal the only way to reduce such artefacts is to replace
the raw data in the vicinity of the metal implant [106].
Standard metal artifact reduction algorithms (MAR) are
based on inpainting techniques, such as FSNMAR [107],
IMAR [108], or OMAR [109].
In summary, CT systems comprise up to 100 detector
rows and allow for routine acquisitions with spatial reso-
lution on the order of 0.5 mm within scans that take less
than a second to a few seconds at dose value ranges of
sub mSv to 15 mSv. CT images are highly quantitative
and reproducible and come with very good contrast
resolution. The most dominant artefacts are addressed
by dedicated correction algorithms. Dual-energy CT ac-




Future CT systems may be equipped with novel X-ray
detectors (Fig. 10). Currently-available detectors are in-
direct converters that convert X-ray photons into visible
light, which is then converted into an electrical current.
The next generation of CT systems may utilize photon
counting detectors, which directly convert the X-ray
photon into an electric signal. In contrast to the indirect
converters, the bell-shaped electric signal that is gen-
erated in the photon counting detector pixel following
the registration of an X-ray photon, is very short in
time – short enough to be able to count a photon
before the next photon arrives. Moreover, the height
of the peak can be measured. Since it is proportional
to the photon energy, photon counting detectors will
be energy-selective, thus, inherently producing spec-
tral information without the need to generate two dif-
ferent X-ray spectra (DECT) [110]. It is assumed that
a future photon counting CT may distinguish four
energy bins, thus, the yielding information similar to
that from a conventional CT scan performed at four
different tube voltages.
Apart from the inherent capability of performing spec-
tral separation, photon counting detectors also promise
to yield images with lower noise levels or to acquire im-
ages at lower patient exposure levels. Furthermore, iod-
ine contrast will be increased with photon counting
detectors. Conventional detectors give a high weight to
high energy photons and a low weight to low energy
photons, including those that are close to the k-edge of
iodine (33 keV). In contrast, photon counting detectors
weight low and high energy photons equally and, thus,
yield improved iodine contrast.
Machine learning (ML)
ML has entered the field of CT imaging and will gain
importance, not only for computer-aided diagnosis and
big data evaluation, but also for CT image formation.
For example, image reconstruction may benefit
from deep learning approaches to help reduce patient
exposure or improve image quality [78, 111] (Fig. 11).
In summary, CT technology is evolving towards im-
ages with spectral information at significantly higher
spatial resolution and greatly reduced noise. These
development will positively impact oncology imaging
applications, such as assessing the thorax, or the
characterization of bone metastases. Further, the
characterization of low contrast lesions will be im-
proved. The added spectral information, which will be
available on demand, may benefit from the develop-
ment of new contrast agents. These advances will
likely find their way into PET/CT systems to improve
attenuation correction and increase soft tissue con-
trast even for low-dose CT scans (Table 1).
Magnetic Resonance Imaging (MRI) and
instrumentation trends
MRI is founded on the principle of nuclear magnetic
resonance (NMR), whereby spin-carrying nuclei under a
strong static magnetic field (B0) can be excited with a
weak oscillating radiofrequency (RF) field (B1) and ab-
sorb its energy [112–114]. The observation that the re-
laxation time constants of the NMR signals are different
between normal and cancerous tissues preceded the ad-
vent of MRI [115]. In MRI, magnetic field gradients (G)
are used to make the frequency and phase of the spin
precession spatially dependent and, thus, produce an
image of the signal emitting spins [116, 117]. Compared
to other imaging modalities, such as CT and PET, MRI
has the intrinsic advantage of providing multifaceted and
excellent image contrast, especially for soft tissues, and
for not utilizing ionizing radiation. MRI can also be per-
formed in any orientation without relying on postproces-
sing image reformatting. Conversely, MRI has an
intrinsic limitation in signal-to-noise ratio (SNR), and
because most MRI schemes rely on acquiring one line of
k-space at a time, it has been relatively slow.
Status quo
Magnets and gradients
In the magnet technology, the superconducting magnet,
active shielding, and “zero helium boil-off” are a few sig-
nificant milestones that have helped shift MRI from be-
ing low field (0.1 – 0.2 T) in the early days to the
present day of high-field systems (1.5 – 3.0 T) as the
standard. A strong motivation for the development is
the increased intrinsic SNR, which is approximately pro-
portional to B0. Unfortunately, higher magnetic field
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strength also entails technical challenges, including
higher magnetic susceptibility and higher RF field dielec-
tric effects. On the other hand, the development of faster
and more powerful gradients, including better eddy
current management with actively shielded gradients
and real-time compensation strategies, has largely been
motivated by fast imaging, such as echo planar imaging,
fully-balanced steady-state imaging, and fast spin echo
imaging. The successful implementation of these fast im-
aging techniques has brought to fruition of novel clinical
applications, such as blood oxygen level dependent or
BOLD functional MRI, and diffusion weighted imaging
(DWI), which has found application in early detection of
stroke and providing better characterization of tumours.
RF coils
Similar to magnet and gradient innovations, the RF tech-
nology for MRI has also been undergoing a steady
stream of development. In the early days of MRI, a sin-
gle “one-size-fits-all” RF coil was often used for both
transmit and receive. The phased-array technology [118]
is a major step forward in MRI as it provides simultan-
eously the large coverage of a volume coil and the super-
ior SNR of a small surface coil. The phased-array coils
have also enabled parallel imaging [119–121] and simul-
taneous multi-slice (SMS) imaging [122], which greatly
speed up the MRI acquisition by combining the different
spatial sensitivity profiles of the different coil elements
with magnetic field gradient for spatial encoding.
Similarly, phased-array coils also enable parallel RF
transmit [123], which has the potential for tailoring the
excitation profiles (e.g., for spatially focused excitation
or reduced dielectric artefacts). For these and other ad-
vantages, many present-day MRI scanners carry a wide
variety of phased array coils and are equipped with up to
128 or more simultaneous RF channels.
Oncology protocols
From its very beginning, clinical applications, such as in
cancer, have always been the underlying driving force
for the development of MRI. The versatility of MRI is
reflected in many different types of images that can be
generated with the different scan protocols, pulse se-
quences and image reconstruction algorithms. Among
them, T1-weighted and T2-weighted images, in conjunc-
tion with Gadolinium-based contrast agents, have been
the mainstay for most oncological MRI applications, es-
pecially for the detection, characterization, and staging
of the tumours (Fig. 12). The development of the fast
spin echo (alternatively known as turbo spin echo, or
RARE) pulse sequence [124], which employs a train of
rapidly refocused echoes after each excitation to fill mul-
tiple lines of k-space, greatly reduces the acquisition
time for T1-weighted or T2-weighted images. Many
magnetization preparation schemes have also been de-
veloped to further enhance the utility and versatility of a
basic pulse sequence, such as inversion recovery for fluid
attenuation (FLAIR) [125] or chemical shift selective sat-
uration (CHESS) for fat suppression [126].
Fig. 11 Patient exam reconstructed with FBP (left), an iterative algorithm (middle) and a deep learning (DL)-based approach (right). The potential
of DL-based CT image reconstruction is illustrated by the significantly lower noise levels while with preserving image detail and increasing
visibility of low contrast structures. Courtesy of GE Healthcare
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Multi-parametric MRI
In addition to stationary tissues, MRI can also be used
for imaging moving blood or cerebral spinal fluid (CSF)
in MR angiography (MRA) to detect and depict vascular
abnormalities. For this application, several MRA
methods have been developed and are in routine clinical
use. Contrast-enhanced (CE) MRA relies on the injec-
tion of a Gd-based contrast agent to shorten the T1 of
the blood, thus, creating enhanced signal for the blood
relative to the background tissues. Time-of-flight (TOF)
MRA, on the other hand, relies on the inflow enhance-
ment of the blood signal and various saturation tech-
niques to suppress the signal from the stationary
background tissues. Although less robust and usually of
lower spatial resolution, TOF-MRA does not require
contrast agent injection.
Compared to other imaging modalities, a unique fea-
ture of MRI is that its signals have complex rather than
scalar values. The velocity of the moving spins, such as
from blood, can be encoded into the phase of the MR
signals through the application of magnetic field gradi-
ents. Phase-contrast (PC) MRA is based on this principle
and compared to CE- or TOF-MRA, has the advantage
of being able to quantitatively measure the blood flow
[127]. PC-MRI is also the basis of MR Elastography
[128], which can measure the tissue stiffness and has
been successfully applied for staging liver fibrosis and
differentiation between benign and malignant tumours.
Another important application where the phase of the
MRI signals is successfully manipulated is Dixon im-
aging [129], by which water and fat in the tissue can be
separated with a combination of modified data acquisi-
tion and postprocessing. Dixon imaging, in combination
with the segmentation of bone and air by a zero-TE
(ZTE) pulse sequence, has also been useful for creating
the attenuation maps that are needed for accurate PET
reconstruction in the combined PET/MR systems [130].
In addition to the conventional T1, T2, and proton
density-weighting, several alternative contrast mechanisms
in MRI have been developed and found their value for im-
aging of cancer. Diffusion-weighted imaging (DWI) en-
codes the Brownian motion of water molecules into the
signal loss through the application of large diffusion-
sensitizing gradients. Unlike the image contrast by T1 and
T2, which is generally related to “water content”, diffusion
contrast is sensitive to changes in the intra- and extra-
cellular structures and density. Further, DWI images can
be used to generate an apparent diffusion coefficients
(ADC) map, which can serve as a quantitative marker for
tissue characterization without requiring an exogenous
Fig. 12 A 59-y/o female presented with palpable mass of right upper breast. Biopsy revealed intraductal carcinoma (IDC) grade III. (a) Digital
mammography cranial-caudal (CC) views of both breasts. Notice the lesion (arrows) was poorly delineated due to dense breast. (b) Mediolateral
oblique (MLO) view indicates longest dimension of lesion to be 4.3 cm. (c) Under targeted US, the lesion was seen as ill-defined hypoechoic mass
with longest dimension of 4 cm. Axial and sagittal post-contrast, fat-suppressed dynamic contrast enhanced (DCE) MRI shows the lesion of a
much larger extension at 7.3 cm and avidly enhancing (d and e, arrows). (f) Axial fat-suppressed T2-weighted image shows the large carcinoma
(arrows) as hyperintense lesion involving most of the upper part of the breast. Images courtesy of Maia Rauch, MD, PhD
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agent. In cancer applications, restricted diffusion and low
ADC have in general been found to correlate with cell ma-
lignancy and aggressiveness [131]. DWI also serves as the
basis for diffusion tensor imaging (DTI) [132], which mea-
sures the diffusion anisotropy of the underlying tissues
and has been useful for preoperative planning by depicting
the relationship between brain tumours and adjacent
white matter fibre tracks (Fig. 13).
Chemical exchange saturation transfer (CEST) imaging
[133] is an MRI contrast mechanism that relies on the
magnetization transfer [134] and chemical exchange be-
tween the protons of water and the protons of some la-
bile macromolecules, such as the mobile proteins or
peptides. The detection of these macromolecules with
CEST is indirect, yet with a sensitivity that is enhanced
by orders of magnitude compared to the detection of
water. Interestingly, CEST can measure not only the
concentration of these macromolecules but also the
pH-level of their environment because the latter is
dependent on the rate of magnetization transfer and
chemical exchange. Since the accumulation of the
macromolecules and pH-level of their environment
that are measurable by CEST are sensitive to the can-
cer metabolism and progression, there has been an
intense interest in investigating the potential of CEST
for a variety of cancer applications, including for im-
proved detection, characterization, and treatment re-
sponse assessment.
In summary, MRI has established itself as a modality
of choice in the detection, characterization, and staging
of cancers of many types, including those of the brain,
spine, liver, prostate, rectum, and breast. Many technical
limitations of MRI of the early days (e.g., speed, SNR,
and motion artefacts) have become increasingly well-
managed. Thanks to the excellent soft tissue contrast
and the growing number of useful contrast mechanisms,
MRI is an indispensable tool for imaging of cancer.
Status go
Hardware
Wide-bore scanners with light-weight and more anat-
omy conformal phased array RF coils will become in-
creasingly available, making MRI more patient friendly
and less time-consuming to operate. Hardware enhance-
ments with anatomy-dependent adaptive shimming,
such as in the areas of C-spine/neck and shoulders, and
more accurate and easy-to-use motion monitoring/man-
agement devices are also expected to substantially im-
prove the image quality and reduce the scan-to-scan
variability.
Dual-modality combinations with MRI
MRI has been integrated successfully as a major compo-
nent in a couple of dual-modality systems, such as PET/
MR [135, 136] and MR-Linac [137]. PET/MR, in particu-
lar, will be used to explore the value of quasi-
simultaneous acquisitions of metabolic information from
PET and morpho-functional information from MRI (e.g.,
T1, T2, DWI, perfusion, CEST) for tumour
characterization [45]. It should be recognized, however,
that key applications remain to be identified and estab-
lished in clinical routine. There is evidence that the high
soft tissue contrast of MR and its simultaneous acquisi-
tion with PET data are useful for accurate local staging
and treatment assessment of several types of tumours,
such as gynaecological and prostate tumours, and that,
therefore, fully-integrated PET/MRI could potentially be
regarded as advantageous over PET/CT (Fig. 14). With
regard to MR-Linac, the superior soft tissue contrast and
ability to continuously image a moving tumour (e.g., in
the liver or lung) and its surrounding anatomy by MRI
can be leveraged to guide and optimize the treatment of
the tumour by external beam radiation and minimize
the radiation damage to the normal tissues. The poten-
tial for functional assessment of the tumours by MRI is
also an advantage over the traditional and more estab-
lished CT-guided radiotherapy.
Speed and SNR
Several novel and exciting techniques are emerging to
further increase the speed and SNR in MRI. Compressed
sensing [138], which employs the image sparsity, random
Fig. 13 Functional MRI (fMRI) and diffusion tensor imaging (DTI)
tractography for presurgical evaluation of brain tumour resection.
Significant fMRI activations were detected in both anterior (Broca’s)
and posterior (Wernicke’s) areas of the language network in the left
hemisphere when the patient was performing language tasks (blue:
word generation, pink: category naming, yellow: sentence
completion). Critical fibre bundles including corticospinal tract
(motor) and arcuate fasciculus (language) were generated with
fibre tracking of the DTI data. (Images are courtesy of Ho-Ling
Liu, PhD)
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undersampling, and non-linear iterative reconstruction,
enables MRI beyond the Nyquist limit without a major
resolution loss. In conjunction with parallel imaging,
compressed sensing is poised to become an important
acceleration option for many MRI acquisition. MR Fin-
gerprinting [139], which allows quantitative mapping of
multiple tissue parameters simultaneously with a single
acquisition and postprocessing pattern recognition with
the aid of a pre-established signal dictionary, has the po-
tential to become a useful tool for tissue parameter
quantitation and detection of a target disease change
with high sensitivity.
Machine learning
As for other imaging modalities, artificial intelligence
(AI) and machine learning (ML) have the potential of
bringing about the most disruptive changes to MRI
[140]. Although still considered at its infancy, AI/ML
has demonstrated an array of remarkable applications
in MRI data acquisition and image reconstruction
(e.g., for speed acceleration, resolution enhancement,
and generation/synthesis of multiple image contrasts
including across the different modalities), in image
processing (e.g., automatic artefacts removal and
denoising without blurring) (Fig. 15), and in image
analysis and direct diagnosis (e.g., automated tumour
and anatomy segmentation, image co-registration, and tis-
sue parameter estimation without relying on empirical
modelling, classification of tumour type, grade, and treat-
ment response). AI/ML has also been successfully applied
for practice efficiency improvement through protocol de-
termination based on short-text classifications, for
Fig. 14 A 65-y/o female with ovarian cancer. (a) Axial contrast-enhanced CT shows ascites and peritoneal enhancement (arrows) of concern for
peritoneal disease. (b) Post-contrast T1-weighted MRI shows enhancement and nodularity in the pelvis along the peritoneal lining (arrow) and
thickening of the sigmoid colonic wall (fat arrow) of concern for peritoneal disease. Serosal involvement of the sigmoid colon may require
colonic resection. (c) Axial fused PET/MR shows [18F]FDG-avid lesions along the pelvic peritoneal lining (arrow) and along the sigmoid colonic
wall (fat arrows) representing peritoneal disease and serosal involvement of the colonic wall, which may require resection of the sigmoid colon.
Images are courtesy of Priya Bhosale, MD
Fig. 15 3-T high-resolution axial T2-weighted images of a patient with adenocarcinoma of rectosigmoid junction. (a) Image acquired with a
standard clinical protocol with a number of signal excitations (NEX) of 2, with arrow showing a mass with irregular infiltrative margins. (b) Image
acquired with an identical scan protocol and patient setup, except with the NEX reduced to 1 and thus scan time reduced by half as compared
to (a). An expected reduction in SNR is noted. (c) Image generated from a DL-reconstruction algorithm using the same acquisition as in (b).
Notice the restoration of SNR without loss of resolution compared to (b)
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substantially reduced Gd-dosage in contrast-enhanced
MRI without a noticeable reduction in image quality, and
for generating synthetized images used for PET/MR at-
tenuation correction. There is little doubt that the list of
AI/ML applications in MRI will grow rapidly. However, it
is also important to note that many challenges remain for
these applications to be translated into clinical practice,
among them cross-site validation of a trained model/algo-
rithm, clinical workflow integration, and regulatory
hurdles.
In summary, MRI is expected to continue to evolve
and expand in technical scope and clinical applications.
In addition to becoming more patient- and user-friendly,
MRI is poised to break some fundamental boundaries
(such as in speed, sensitivity, and artefact removal) with
several emerging technologies, including compressed
sensing and deep learning (Table 1). The improved
image quality and the accuracy and reliability of the
quantitative MRI measurements will be highly valuable
in better tumour characterization and in better longitu-
dinal assessment or cancer prognostication.
Ultrasound (US) imaging and instrumentation
trends
Ultrasound (US), also referred to as sonography, is a
non-invasive imaging method that employs sound waves
to generate images of the inside of the body. US is based
on high-frequency sound waves that are emitted from a
transducer that is placed on the body surface over the
volume of interest. The same transducer is used to re-
ceive the sound waves, which are reflected by the target.
Depth-encoded US images can be generated by deter-
mining the run time of the reflected sound waves within
the tissue. Because of the ease-of-use and widespread
availability, US is used frequently as the first diagnostic
imaging modality during a patient work-up. This is true
for investigations of most soft tissues, except the lungs
and the brain. The key advantages of this imaging mo-
dality are the lack of radiation, its real-time imaging cap-
ability, low cost and high mobility of the devices.
Status quo
US-imaging strongly evolved over the last decades [141].
State-of-the-art transducer technology supports the re-
cording of the higher harmonics of reflected ultrasound
pulses (harmonic imaging), thereby, improving image
quality, in particular for deeper layers of tissue. Signifi-
cant advances, with respect to the field-of-view and the
transition from 2D to 3D data assessment, have been
achieved by introducing moving transducer arrays inside
handheld instruments, e.g., for breast imaging [142, 143].
Real-time 3D data acquisitions are made possible with
phased array volumetric ultrasound scanners [144].
However, specific design aspects of the transducer
matrix including cross-talk between elements and size
and number of elements render the fabrication of matrix
transducers difficult and costly [145].
Next to volumetric imaging, also other technologies,
such as ultrasound elastography (USE) have been devel-
oped to extend the field of ultrasound applications.
Transducers capable of strain or shear wave imaging
support the non-invasive characterization of the mech-
anical properties of tissues. Given the differences in tis-
sue elasticities in specific pathologies, such as organ
fibrosis and tumours, USE has became a valuable diag-
nostic tool for the differential diagnosis of healthy and
diseased tissues. For example, USE of the breast can be
applied to differentiate between benign and malignant
lesions, given that malignant lesions appear more het-
erogeneous and are stiffer than surrounding healthy tis-
sues [146, 147]. The combination of Brightness-mode
(B-mode) US with USE further improves the specificity
to detect vital malignant tissue and reduces the number
of required biopsies [148, 149]. Chronic thyroiditis and
malignant tumours are associated with higher stiffness,
thus, making USE a valuable tool for malignancy assess-
ment of nodules and biopsy guidance (Fig. 16) [150].
In addition to the evaluation of mechanical tissue
properties, the aberrant vasculature in tumours is of
high interest for tumour characterization and therapy
monitoring. Doppler methods, which use deformations
of sound waves reflected from moving elements in the
blood to visualize blood flow, enable a detailed vascular
characterization not only for assessing plaques and sten-
oses in larger vessels, but also to detect larger neoplastic
vessels. However, at clinically applied frequencies the
very fine vascular networks can still only be detected
with contrast-enhanced US (ceUS) scans. Today, a var-
iety of commercial and clinically approved contrast
agents is available [151]. These agents are based on
microbubbles with a size of 1-3 μm, which can be sepa-
rated into a gas core and a shell material [151]. Micro-
bubbles can be destroyed and, thereby, detected by
highly energetic US (e.g., Power Doppler imaging) or
non-destructively detected by harmonic imaging by their
non-linear responses, e.g., using amplitude modulation
and pulse inversion sequencing modes [152–155]. In
particular, ceUS is used in clinical routine for the
characterization of liver lesions [156], thereby signifi-
cantly improving tumour characterization as well as sup-
porting early and specific therapy response assessment
[156, 157]. Consequently, many clinical guidelines now
mention ceUS imaging as a diagnostic option [158–160].
Next to diagnostic applications, US can also be used for
therapeutic applications. Therapeutic high-intensity fo-
cused ultrasound (HIFU) applications were developed that
are often combined with diagnostic US imaging [161]. Fo-
cusing US pulses to a defined location in tissue can lead to
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a regionally defined energy deposition. Depending on the
settings, thermal or mechanical effects can be induced,
known as thermal ablation or histotripsy. So far, HIFU is
approved by the FDA for six indications, including uterine
fibroids, benign and malignant prostate lesions, essential
tremor, tremor dominant Parkinson’s disease, and bone
metastases [162].
In summary, low cost and lack of radiation make US
a frequently used imaging modality for first-line investi-
gations, intermediate follow-up investigations during
pharmaceutical therapies and interventions. In this con-
text, its anatomical and vascular imaging capabilities are
of particularuse and applied together.
Status go
Three-dimensional US imaging
Advances in the development of micromachined ultra-
sound transducers might enable to overcome current
limitation in the number and positioning of elements in
matrix transducers [163]. However, the control of far
more than 256 channels in parallel is necessary to make
use of the full potential of these transducers, and to
maximize image quality. Next to a higher number of ac-
tive transmit and receive elements, the image quality
could also benefit from image reconstruction using 3D
datasets.
Ultrafast US imaging and US localization microscopy
Conventionally, the elements of an ultrasound probe
are excited sequentially, whereby the number of lines
determines the frame rate and thus, the speed of the
image generation. Novel ultrafast imaging systems are
capable of computing all lines in parallel [164].
Therefore, an ultrasound image can be computed
from a single transmit pulse. However, image gener-
ation is limited by the propagation speed of sound in
the medium. Using ultrafast scan technologies in
Doppler, the motion of individual blood cells or
microbubbles can be tracked [165]. Displaying these
tracks in the size of the blood cells, images of the
vasculature are obtained that exceed the resolution
limit of the scanner (Ultrasound Localization Micros-
copy, ULM). As an alternative to ultrafast data acqui-
sition, contrast-enhanced US helps generate super-
resolution images at lower frame rates if motion
models are applied to assign the detected microbub-
bles to vascular tracks [166]. This method is termed
motion-model Ultrasound Localization Microscopy
(mULM). Generally, ULM enables the analysis of the
vascular architecture (e.g., vessel length and branches)
with an interpolated spatial resolution of a few micro-
meters. At the same time, functional information (i.e.
blood flow velocity) can be acquired. Opacic et al.
first successfully applied mULM in patients and dem-
onstrated responses to therapy in breast cancer pa-
tients (Fig. 17) [166]. There remains room for
improvement regarding the adaptation of the algo-
rithms used in pre-clinical experiments to the clinical
situation, where scanners work at different frame
rates, ultrasound frequencies and in cases of more
significant motion [167]. Once this is achieved, clin-
ical studies need to prove the additional value of
super-resolution ultrasound for various applications,
such as malignancy assessment or treatment
monitoring.
Molecular ultrasound imaging (MOUS) has been
shown to detect therapy responses earlier than normal
ceUS during anti-angiogenic therapies (Fig. 18) [168].
Fig. 16 Ultrasound elastography. Elastography (colour-coded) and B-Mode images of a thyroid adenoma (a) and a papillary carcinoma (b) with
the lesions encircled in white. The elastography images show clear differences and, thus, help characterize the carcinoma through reduced
elasticity, as depicted by the blue regions, which correspond to a lower elasticity (image adapted from [150])
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Clinical studies using BR55, microbubbles targeting the
endothelial biomarker vascular endothelial growth factor
receptor 2 (VEGFR2), have shown their safety and use-
fulness for cancer detection in ovarian, breast and pros-
tate lesions [169, 170]. Clinical studies are currently
initiated to identify whether and how this information
about VEGFR2 can improve clinical decision making in
primary diagnosis, cancer characterization, therapy se-
lection and monitoring.
Hybrid US imaging (HYBUS)
Combined, or hybrid imaging typically relies on hard-
ware combinations of complementary imaging
methods. To date, US has not entered the hybrid im-
aging field beyond pilot field developments. Tavitian
and his team did propose a triple-modality imaging
device, by adding ultrafast ultrasound to a PET/CT
system, and investigating the energy metabolism and
vascular architecture during tumour growth at the
same time [171]. In the future, we may see efforts to-
wards integrating US into PET and also MRI systems,
so as to overcome the intrinsic spatio-temporal limi-
tations of these modalities through ultrasound-based
motion correction during image reconstruction [172].
US-guided motion compensation of PET data may be
explored in the future for tracking more complex,
non-respiratory motions as well.
High-intensity focused ultrasound (HIFU)
The future of HIFU is likely to be MR-guided, so as to le-
verage high spatial resolution and soft tissue contrast of
MR images to delineate a target lesion and its surrounding
normal anatomic structures, and to use MR for real-time
thermal dose control and treatment monitoring. The use
of HIFU can be combined with drug delivery triggered by
US-induced hyperthermia or mechanical effects, which
can further help in reducing potential tumour relapse
from the ablation site [173].
Sonoporation and sonopermeabilisation
When microbubbles enter the ultrasound field, they
begin to oscillate (stable cavitation). If the amplitude ex-
ceeds a certain threshold, the microbubbles undergo
Fig. 17 Super-resolution ultrasound. (a) Ultrafast Ultrasound Localization Microscopy (uULM) uses ultrasound devices with very high frame rates
to achieve reliable tracks of microbubble movements. (b) In motion-model Ultrasound Localization Microscopy (mULM) tracks between voxels
that are enhanced by microbubbles are generated, and their likelihood is calculated using a motion probability model. Three potential
combinations are schematically displayed, with the green track symbolizing the highest probability. In uULM and mULM the diameter of the
tracks is defined to be close to the size of microbubbles, and super-resolution images of the vasculature are generated. (c) B-Mode image of a
breast cancer in a patient (encircled in white). (d) mULM based velocity map of a breast cancer in a patient. (e) The corresponding flow direction
map, deriving from mULM analysis, provide important information about vessel maturity (image adapted from [166])
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inertial cavitation, that is they vigorously oscillate and
eventually collapse, thereby generating high speed air
jets, which can permeate cell membranes. Both, stable
and inertial cavitation, can be used to overcome bio-
logical barriers. Sonoporation describes US applications
with the intent to improve the transport of drugs or
genes through pores generated in cell membranes, while
sonopermeabilisation gears towards overcoming vascular
and stromal barriers, such as the blood brain barrier
(BBB) or matrix fiber networks in desmoplastic tumours.
Carpentier et al. showed in a phase I study that repeated
and transient BBB opening can be achieved and is well
tolerated [174]. In another clinical study, inoperable pan-
creatic cancer patients were treated successfully with
gemcitabine in combination with microbubbles and
ultrasound [175]. Despite these promising results, exten-
sive characterization, optimization and safety assess-
ments are required to identify the best setup and
settings for its purpose while preventing unwanted and
irreversible injury of the tissue. Especially in the treat-
ment of very stromal tumours, as well as for drug deliv-
ery across the BBB, sonoporation may improve therapy
efficacy and outcome in the future.
In summary, the diagnostic and therapeutic potential
of US will be explored through translation of early
pre-clinical developments. US offers microvascular
characterization at almost microscopic level in humans
and provides important functional and molecular charac-
teristics that can be used for tissue characterization. In this
context, the use of computer-assisted lesion detection and
automated image analysis will decrease user-dependency
of the modality. Radiomics analysis of ultrasound data will
further increase the accuracy and diagnostic impact [176].
In addition, new therapeutic applications of US, e.g., to ab-
late tissue or to improve drug delivery are emerging. In
conjunction with other imaging modalities, US can, thus,
be expected to play a significant role in theranostic im-
aging in the future.
Optical imaging and instrumentation trends
Optical imaging instrumentation encompasses a large
variety of technologies ranging from aided visual
inspection using magnifying glasses or video endo-
scopes, to light microscopy, as well as techniques that
require computational efforts to generate diagnostically
relevant information. Two thirds of the medical
Fig. 18 Use of VEGFR2 targeted microbubbles to assess perfusion and angiogenic target expression within the same ultrasound examination. (a)
Schematic presentation of a typical time-intensity curve using targeted microbubbles. The numbers refer to the respective time points of the
images shown in (b). (b) The upper row shows US images of untreated experimental breast cancers in the contrast mode, the bottom row
tumours treated with anti-VEGF antibodies (B20). The microbubble accumulation in the wash-in phase is clearly reduced in treated tumours,
indicating a breakdown of vascular function. Consequently, there is reduced binding of VEGFR2 targeted microbubbles in the treated tumours.
Destruction of the microbubbles by US confirms that they were stationary at the target (right images) (image adapted from [168])
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imaging market are defined by optical instrumentations
with a mainstay in ophthalmology and endoscopy [177].
With its unique spatial resolution capabilities, optical
imaging can be used to assess subcellular structures as
well as mesoscopic details of tissue and organs.
Status quo
Given its limited imaging depth, optical imaging is
used mainly to study easily accessible outer surfaces
of organs, such as the skin or the inner lumen of or-
gans that can be reached by endoscopes or catheters,
such as cardiovascular system, the gastrointestinal
tract, oral cavity, larynx down to the lung, bladder
and urethra, cervix and uterus. The deepest non-
invasive penetration is achieved through the eye down
to the retina, thereby making use of the natural trans-
parency of the ocular media. Optical coherence tom-
ography (OCT) is applied with great success in the
eye as well as through endoscopes in inner organs
[178]. Deeper penetration in tissues can be achieved
by diffuse optical spectroscopy and tomography
(ODT), which has been successfully combined with
non-optical imaging technologies, such as CT, or
photo- or optoacoustic imaging (PAI) [179]. Further,
Cherenkov luminescence imaging (CLI) is currently
being explored for deep optical imaging [180, 181]. In
case of invasive intra-surgical application, optical
technologies can guide precise tumour excision and
help to spare vessels to avoid excessive bleeding.
Fluorescence markers are used to enhance image con-
trast in optical imaging, so as to support tumour
detection and image-guided interventions during biop-
tic sampling and surgical excision.
Light microscopy is the workhorse of standard histo-
pathologic tissue assessment. However, the entire proced-
ure, from tissue sampling to a stained histology, is
complex and time consuming. Timelines are critical, in
particular during surgical intervention, when tumour
borders need to be separated from healthy surrounding
tissues. Even when using faster cryo-fixation of biopsies,
the examination is still done on stained samples by a path-
ologist outside the surgical room, which makes it impos-
sible to assess the full tumour margin. This results in
inadequate tumour resections with reported 20-70% of
cases in breast cancer surgery, or 85% of cases in head and
neck surgery [182]. Additional surgery may be required,
thus, impairing the quality of life of these patients.
Contrast agents
The identification of early-stage cancer is supported
by optical imaging technologies. For example, fluores-
cent markers, such as indocyanine green (ICG), 5-
Aminolevulinic acid (5-ALA) [183] or hexyl-
aminolevulinate (HAL - Hexvix®) [184] help to delin-
eate tumour boundaries and highlight suspicious tis-
sue regions that go undetected with standard white
light illumination. Additional biopsy analysis is still
required that benefits from guidance by narrow band
imaging (NBI) [185], or optical coherence tomography
(OCT).
NBI is limited in penetration depths to 100 μm, or less,
thus, visualizing only superficial vessels. OCT, on the
Fig. 19 OCT and OCTA of basal cell carcinoma. Scale bar: 1 mm. (a) Standard white light dermatoscopy image of the lesion; (b). H&E stained
biopsy taken at the dotted line in (a) indicating the lesion as dark purple area; (c) optical coherence tomography (OCT) scan across the lesion
along the dotted line in (a); (d) OCT angiography (OCTA) with colour depth coding for the depth range between 0.1 and 0.5 mm below the skin
surface exhibiting a characteristic pattern of neovascular growth to the tumour and with large vessel close to the surface. (reproduced with
permission from Wiley and Sons from [189])
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other hand, exhibits better penetration into tissue (down
to 2mm) depending on the centre wavelength and tissue
type. OCT, and its functional extension OCT angiography,
allows to determine the cancer stage by assessing the ac-
tual invasiveness of the tumour growth, which is an im-
portant parameter to affect treatment decision [186–188]
(Fig. 19). Fluorescence Medical Imaging (FMI) has proven
effective in various scenarios of intra-surgical guidance.
ICG selectively accumulates in tumour cells, presumably
due to the enhanced permeability and retention (EPR) ef-
fect [190]. Over the last years, FMI or PDD have become
important diagnostic tools for brain tumour resection and
for the detection and delineation of bladder cancer. Both
methods have helped improve surgical treatment of
patients with cancers of the breast, ovaries and cervix
(Fig. 20). Recent studies suggest that surgeons are able to
resect cancerous lesions smaller than a millimeter in size
using FMI guidance [192, 193].
Resolution versus penetration depth
While optical imaging methods exhibit high spatial reso-
lution, their penetration depth is limited by dominant
scattering and absorption effects. Scatter decreases with
wavelengths in the visible range, while for longer wave-
lengths water absorption becomes the dominant effect.
The absorption coefficient depends on molecular dy-
namics and exhibits local maxima (resonances) and
minima. In general, medical optical windows are centred
at local minima of the water absorption curve at 800 nm,
1060 nm, or 1300 nm.
Diffuse optical spectroscopy (DOS) is a well-established
medical imaging technology, that operates in these op-
tical windows with reduced scattering and water absorp-
tion. It extracts absorption and scattering spectra from
deep within tissue associated with concentrations of en-
dogenous and exogenous contrast agents [194]. For ex-
ample, changes in oxygen saturation indicating the
balance between oxy- and deoxyhemoglobine, can be
used as a sensitive biomarker of tissue pathologies and
for monitoring the effects of therapy [195, 196]. How-
ever, the advantages of DOS come at the expense of low
spatial resolution.
Optical coherence tomography (OCT) acts as a link be-
tween high resolution and low penetration cellular mi-
croscopy on the one hand and full organ and body
imaging with low spatial resolution on the other hand.
Today, it has become a reference standard in ophthalmic
diagnostics, with a growing field of applications also in
other medical disciplines [178]. OCT is capable of pro-
ducing label-free angiographic maps in 3D, called OCT
angiography (OCTA), which has been quickly translated
to diagnostic imaging in ophthalmology and dermatol-
ogy [188, 189, 197].
In summary, optical imaging has a long tradition in
medical diagnostics, given its unprecedented spatial
resolution. Apart from histopathology, optics is widely
used in endoscopy, dermatology, and ophthalmology.
The most recent optical technique that was successfully
translated to the clinics is OCT and OCTA Both provide
cross-sectional images of tissue and vasculature with high
spatial resolution and with millimeter deep penetra-
tion butwith limited tissue specificity. Fluorescence med-
ical imaging significantly improves surgical treatment,
thus, resulting in increased life expectation of patients.
Status go
Currently there are many exciting developments of med-
ical optical technologies in oncology that aim at
Fig. 20 Fluorescence Medical Imaging (FMI) of ovarian cancer metastases: images of retroperitoneal lymph nodes containing metastases of
ovarian cancer (a) and superficial peritoneal metastases of ovarian cancer (b); Left column: white light images revealing low contrast for the
lesion areas; middle column: NIR fluorescence images by FMI; right column: fused white light and FMI images for increased contrast of focal
mestastases. (reproduced from [191] with permission from AACR Publications)
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improving diagnostic specificity, treatment guidance and
surgical guidance.
Deep tissue imaging
Optical imaging techniques are mostly confined to
superficial lesions due to physical limitations of light
propagation. Opto- or photoacoustics (PAI), that is the
optical excitation of an ultrasound wave in tissue, al-
lows for deeper tissue penetration (about 1cm) [179,
198]. This method uses absorbing endogenous chromo-
phores in tissue, such as hemoglobin or melanin, but
could potentially also target exogenous contrast agents.
When a short ns-pulse of light is absorbed, it causes
local heating and thermo-elastic expansion. This leads
to a mechanical pressure wave at high frequency, that
propagates to the tissue surface, where it gets detected
by an ultrasound sensor. In a recent multi-centre trial
with over 2000 women with breast cancer, the specifi-
city of combined PAI and US exceeded that of US alone
by 15% with a sensitivity of close to 99%. Advance-
ments in PAI mandate alternative light sources, such as
LEDs, that support fast pulse sequences for higher im-
aging speed. Similar to US, PAI would be have a hand-
held probe head for clinical application, calling for real-
time or quasi real-time imaging to identify anatomically
and pathologically relevant structures [199]. A key
strength of PAI is the ability to sense targeted fluoro-
phores deep inside tissues, in addition to visualizing
vascular structures and providing oxygen saturation
(Fig. 21). Nonetheless, an in-vivo imaging depth of sev-
eral cm is still a challenge for PAI.
Optical Diffuse Tomography (ODT) shares with ODS
the advantage of deep tissue sensing, and overcomes the
spatial resolution challenge by using multiple illumin-
ation and detection directions. Tomographic reconstruc-
tion is based on solving the complex photon diffusion
equation incorporating several assumptions on tissue
geometry and its optical properties [201]. Nonetheless,
in most medical applications the detection space is
single-sided and reconstruction is an ill-conditioned
problem. The addition of complementary structural im-
aging yields the required information to locate optical
sources in depth (Fig. 22).
Fluorescence medical tomography (FMT) is a variant of
ODT providing the depth distribution of fluorophores in
tissue. The method becomes particularly powerful in
combination with targeted exogenous fluorophores emit-
ting in the near infrared region [203].
Cerenkov luminescence imaging (CLI) [180, 181] is an-
other emerging medical imaging modality. The radiation
is a side effect of radioactive decay, due to particles trav-
elling faster than the speed of light in the respective
Fig. 21 Multispectral Optoacoustics Tomography (MSOT) Imaging of breast cancer: (a) X-ray mammography image reveals a > 4 cm,
subcutaneous, non-specific breast tumour; the yellow box indicates the field-of-view of MSOT ; (b) MSOT image of Hb and HbO2 obtained from
the box in (a); increased blood volume is indicated by the yellow arrows; (c) Total blood volume assessed by MSOT is indicative of hyperemia in
the tumour area; (d) Relative lipid concentration assessed by MSOT demonstrates disruption of fat layer in the tumour area (arrow); (e) relative
water concentration assessed by (MSOT). (reproduced from [200] with permission from AACR Publications)
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dielectric medium. Already, there is a variety of PET
tracers available that have been approved by national au-
thorities, thus, giving CLI a potential jump start con-
cerning its clinical translation. Nonetheless, the main
drawback is its inherently low intensity, and strong scat-
tering and absorption at the typical violet to blue spec-
tral region [204].
Multi-modality imaging
A new trend in optical imaging is to replace invasive,
and often erratic removal of tissue during biopsy by op-
tical biopsy, i.e., the pathologic assessment of tissue in-
situ. Through the combination of high structural sensi-
tivity with molecular sensitivity tumour invasiveness and
tumour grading come within reach of multi-modality
optical imaging. Given its excellent spatial resolution,
OCT comes with a high structural sensitivity while exhi-
biting low specificity. The latter could be complemented
by fluorescence imaging, or by infrared or Raman spec-
troscopy [205, 206]. Raman spectroscopy has an excel-
lent molecular specificity that results from excitation of
rotational and vibrational modes of molecular spectra.
The Stokes-shifted emitted light spectrum can be
regarded as fingerprint of the assessed substance and ex-
hibits typical regions and resonances for lipids, proteins,
etc. Raman scattering is, however, a very ineffective
process with less than one photon in a million carrying
valuable molecular information. Combining OCT with
Raman techniques ex-vivo has been shown to provide
insights into urological tumour stages (invasiveness) and
grades [186].
Tumour grade is strongly related to its metabolic ac-
tivity. Metabolites, such as Flavin adenine dinucleotide
(FAD) or Nicotinamide adenine dinucleotide (NADH
and the redox partner NAD+) have been proven valuable
endogenous molecular probes of cell metabolism. Recent
developments in fluorescence lifetime imaging (FLIM)
show significant changes of FAD and NADH lifetime in
tumour versus healthy tissue [207, 208]. Fluorophores
are excited in the short visible wavelength range where
scattering limits large penetration depths. Multiphoton
microscopy, on the other hand, would permit deeper tis-
sue penetration, since the excitation happens at double
or triple the wavelength of single photon fluorescence at
the cost of non-linear optical processes needing spatio-
temporally confined beams with high numerical aper-
ture. The latter calls for close proximity to the tissue,
which during intraoperative application can only be
achieved through additional hand-held scopes. More-
over, the light sources are bulky and expensive, which
limits an easy clinical translation despite promising re-
sults in dermatology [209].
Targeted exogenous contrast agents
Numerous studies have demonstrated the effectiveness
of fluorophore labelling of tumour lesions for enhancing
the outcome of tumour resection in different applica-
tions. Novel targeted molecular contrast agents are,
therefore, extensively studied for precision medicine and
are awaiting approval for clinical translation [210, 211].
Hybrid contrast agents are developed supporting modal-
ities with different and often complementary physical
contrast mechanisms. Microbubbles for example, that
are used in ultrasound imaging, can be modified to in-
corporate fluorescent agents or radionuclides in their
lipid shells supporting US-optical PET imaging. For
Fig. 22 (a) Combined X-ray based digital breast tomosynthesis (DBT) and diffuse optical tomography (DOT) of breast cancer: DBT image; (b) ODT
of total hemoglobin concentration (HbT) in micromoles per liter; (c) ODT of oxygen saturation (SO2), ODT of reduced scattering coefficient (μS) in
cm− 1 at a wavelength of 830 nm. (d) The breast contains a 2.5-cm invasive ductal carcinoma (arrow on (a), black line with arrow on (b-c).
(reproduced from [202] with permission from the Radiological Society of North America)
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combining optical imaging and MRI, fluorescent
quantum dots with different magnetic properties can
be designed to have paramagnetic coatings, or to exhibit
high native relaxivity. The contrast agents can further in-
corporate radionuclide tags to support PET and
SPECT imaging. Such multi-modality contrast agents
would, for example, allow studying their pharmacokinet-
ics on different scales across various imaging modalities,
starting from cell cultures, to preclinical imaging, and fi-
nally to humans.
Compact systems
Optical imaging technologies are attractive due to their
immediate and most intuitive access to tissue and its
pathologic changes. They are easily integrated into
hand-held devices or hand-held applicators, which is
ideal for point-of-care use, as well as for combination
with other established imaging technologies. Point-of-
care, hand-held endoscopes for cervix screening have
been developed and successfully demonstrated by the
group of Ramanujam, in particular addressing global
health disparities in cancer prevention and disease man-
agement [212]. Finally, photonic integrated circuits (PIC)
are capable to realize complex optical setups, including
sensors, modulators, as well as light sources on a single
chip of the size of a cent coin, thus, rendering them
ideally suited for compact devices. In the future, wear-
able devices based on such compact chips may help
monitor health status of subjects and as such become in-
tegral to disease prevention.
In summary, there are many exciting advances of op-
tical technologies to precisely target structure, invasive-
ness as well as the metabolic activity of tumour cells, so
as to replace invasive tissue biopsy extraction. Further-
more, targeting fluorophores or other contrast agents
support precision medicine approaches. Navigating regu-
latory hurdles is key to a faster translation of those novel
molecular probes. Optical techniques are on the way to
reach deeper into tissue without employing ionizing ra-
diation or as in the case of CLI are a natural add-on to
established medical imaging technologies. Non-invasive
optical methods may be easily used for large scale
screening or for longitudinal treatment monitoring. Fu-
ture systems provide flexible resolution from organ level
down to cellular, make use of the richness of informa-
tion that light carries targeting specific tissue and cells,
being compact, mobile, and are easily combined with
other imaging modalities.
A critical perspective
From a wider perspective, evolution of medical imaging
is driven by attempts of making examinations faster,
more accurate and, ideally, easier and cheaper to use.
Requirements and successes differ for individual
modalities. While not exhaustive by design, this section
of the paper will attempt to list a number of contenders
for improving the quality and applications of medical
imaging for cancer patient management (Table 1).
Modalities
The current differentiation between morphological and
functional modalities (Fig. 1) will remain, but the border
between them will likely become blurred. Standard mor-
phological modalities will also provide physiological and
functional information through more advanced imaging
protocols and exploitation of their physical principles
through advanced instrumentation and novel contrast
agents. Traditional functional modalities will also pro-
vide improved morphological cues through new “smar-
ter” instrumentation that not only better exploits the
physical properties of detector materials and design, but
also circumvents current limitations through novel
geometry and processing schemes.
For PET, new total-body designs with enlarged axial
FOVs have confirmed a much-increased sensitivity, and
low spatial resolution has now become the weakest attri-
bute. New detector designs and detailed modelling of
the detector and gantry geometries (incl. Depth-of-
interaction, non-collinearity), as well as improved partial
volume correction, will markedly increase the spatial
resolution up to the physical limits of the modalities.
While a recently launched challenge aims at direct im-
aging through 10 ps TOF PET, further improvements in
the meantime will come from image reconstruction
techniques (e.g., ML/AI-enhanced) that will take the
whole “system” into consideration, that is the subject be-
ing imaged, the probe being used in given protocols, and
the gantry and detector design as well as all necessary
corrections. Another major aspect of PET (and SPECT)
are the molecular probes (aka radiotracers) being used
for imaging and characterization, with development and
validation processes that should be significantly sped up
through more advanced in-silico approaches towards
first-in-human trials, approval, and clinical deployment.
An interesting application, also referred to as “theranos-
tics”, of SPECT and more recently PET, is the use of
similar tracers for imaging and therapy, with either differ-
ent doses or isotopes for each application. In this para-
digm, a low radioactive dose scan, either with the same or
a different radioisotope, acts as a surrogate that can then
be used either directly or through modelling to estimate
the internal dose depositions when the actual therapeutic
agent is delivered. Such applications will likely further de-
velop alongside targeted personalised molecular therapies
that are expected to be much more specific and compre-
hensive than current surgery, or radiotherapy.
For SPECT, there are many similarities with PET. Lar-
ger imaging geometries, this time in the form of ring
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detectors, will significantly improve volume sensitivity,
while the replacement of scintillation detectors with
semi-conductor detectors, and/or the replacement of
photomultiplier tubes with semiconductor light readout
technology will bring significant improvements in energy
and spatial resolution. Progress with collimator design
together with developments in image reconstruction al-
gorithms will bring further improvements to image qual-
ity. These technological advancements will drive the
development of theranostics and image-based dosimetry
which will ultimately widen the appeal and availability of
quantitative SPECT.
For CT, spectral or multi-energy CT has already
shown its potential for identifying different materials
in the FOV and for removing artefacts, which can be
further enhanced through ML/AI approaches. Photon-
counting spectral CT has the added benefit of further
reducing the ionizing radiation dose from the current
lows already afforded by advanced reconstruction
techniques. It will also provide much higher spatial
resolution, thus, further improving the potential of
texture analysis in an advanced analysis regimen.
Since spectral CT can also provide information that is
relevant to the PET and SPECT energy spectra, it has
the potential to produce much more accurate attenu-
ation maps in hybrid modalities (also by unambigu-
ously identifying iodine contrast agent), thus, leading
to much improved corrections and reconstructions.
Naturally, this potential can be reaped only with the
availability of a combined PET/CT offering with spec-
tral CT included, which will depend heavily on mar-
ket needs. In that case, we anticipate that new
contrast agents will also be designed at fast rate that
will provide means to qualify physiological processes
in complement to more functional data.
For MR, the onus will remain on producing images
with better contrast, higher SNR, shorter scan time
(translating into more sequences being included in a
given examination time for expanded multi-parametric
imaging), improved quantification, and higher spatial
resolution. For various reasons, including a still very low
installed base, the potential of high (up to 7 T) and
ultra-high (up from 7 T) fields in the clinic is still un-
clear, but should the inherent technical limitations (e.g.,
homogeneity and artefacts) be successfully addressed,
such machines will likely be very helpful for moving be-
yond the current limitations of lower fields by boosting
speed, intrinsic SNR and imaging sensitivity (e.g., for
fMRI and especially resting state fMRI), while enabling
morphological imaging at sub-millimetre spatial reso-
lution. As with CT, new contrast agents will be designed
to characterize physiological processes. A special case
thereof, which is still not broadly implemented, is hyper-
polarized MR by which intrinsic magnetization is
enhanced by over four orders of magnitude through dy-
namic nuclear polarization (DNP), so as to enable real-
time monitoring of cell metabolic activities, such as in-
creased pyruvate to lactate conversion in cancer (War-
burg effect) [213].
For combined, or hybrid modalities (PET/CT, SPECT/
CT and PET/MR) the expected improvements on each
of their modality components would potentially yield
better corrections (e.g., spectral CT for attenuation and
artefact removal) and soft tissue differentiation (e.g.,
spectral CT again, and faster MR, which will permit
more sequences within an acceptable examination
period). Combined with more detailed modelling of the
imaging instruments, physics and physiology, this will
lead to significantly improved image reconstruction and
more meaningful imaging and derived information. Fur-
ther, axial FOVs of PET/CT systems are prone to ex-
pand in view of the perceived benefits. Likewise, SPECT/
CT may experience a push towards fast and quantitative
whole-body imaging, thanks to recent evidence in clin-
ical pilots. While the technical advancement of fully-
integrated PET/MR systems is hampered by costs and -
still - suboptimal workflow and throughput for a busy
clinic, alterative MR-based combinations, such as
SPECT/MR [214], may move into the focus of attention,
despite similar cost-efficacy concerns. Optical imaging,
in combination with other, complimentary imaging mo-
dalities, or alone will impact clinical routine in oncology
only if the penetration depth challenge can be addressed
adequately for probing deep lesions.
Ultrasound has traditionally been seen as highly user-
dependent and with low reproducibility, but new 3D
transducers will make it more like other tomographic
modalities [215, 216]. This will be combined with soft-
ware that will guide the operator to ensure that all rele-
vant space is scanned and stitched together so that the
corresponding volume can be sliced through and ana-
lyzed in the most optimal orientation, with real-time
performance to build upon the interactive nature of this
modality. Contrast agents (e.g., microbubbles) will be
further used to provide some functional information,
and elastography - ideally through its less user-
dependent shear-wave implementation - should also be-
come more prevalent to assess suspected lesions. When
combined with ultrafast and super-resolution imaging, it
will open further perspectives to microvascular imaging.
While ultrafast US imaging requires more advanced
transducers and systems, super-resolution imaging based
on carefully validated motion models could be applicable
to existing machines. More applications can be envis-
aged through directionally increasing US energy either
directly or through nanotech resonators will lead to fur-
ther applications, such as for heating tissues, making
them more prone to taking up drugs and genes via
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sonoporation, or simply for releasing drugs from nano-
tech capsules at targeted location.
Optical imaging provides targeted molecular contrast
and resolution that is unmatched by other modalities,
and, thus, holds great promises for targeted precision
medicine even though it is still limited for imaging deep
tissue. While this limitation has been successfully ad-
dressed through PAI, BLI or CLI in preclinical and re-
search settings, its translation and reproducibility are
still lagging. Optical imaging can also relatively easily be
combined with other modalities, such as CT, MR or
PET, although this again has mostly been demonstrated
pre-clinically thus far. A successful implementation of
optical imaging is in surgical microscopes, with FMI
soon expected to radically improve the efficacy of cytor-
eductive surgery. While FMI systems are currently lim-
ited in specificity due to the paucity of approved
fluorophores, FLIM may soon leverage such limitation
with several high specificity agents already in the ap-
proval pipeline. Perhaps due to a relative ubiquity and
low cost of adding optical imaging to other modalities,
several multi-modality contrast agents have already been
developed for combinations such as Optical/PET, Op-
tical/SPECT, Optical/MR and Optical/US, but their
translation to the clinic is still pending. As another spe-
cial case currently under clinical evaluation, endoscopic
OCT provides exquisite differentiation of cancer tissues,
also at early and pre-cancerous stages, which can be
combined with additional molecular information and
Raman spectroscopy for a complete pathologic
evaluation.
Photo-acoustic imaging, which uses a laser actuation
and US readout, is a modality that has recently emerged
and combines the pros (and some cons) of both optical
and US imaging to provide an anato-functional insight
into live tissues. With its potential already clearly dem-
onstrated in pre-clinical and research settings, this new
modality is expected to translate to the clinic soon in
combination with specific contrast agents for further
expanding its scope. As with US or optical imaging, it
will likely be combined with other modalities to comple-
ment and expand upon respective findings.
Quantification
In light of the complexities of cancerous disease, qualita-
tive assessment of images appears not sufficient anymore
for detailed and actionable characterisation of extent
and staging, or for advanced therapy response assess-
ment. Accordingly, modern evaluation approaches may
increasingly rely on extracting or deriving quantitative
parameters and information from images, also depend-
ing on their inherent type and the modality they are
stemming from. Such quantitative biomarker informa-
tion may provide additional insight into the stage of a
disease for a given patient (e.g., lymphoma), where exist-
ing consensus criteria have been shown to work well
already, or it may soon surpass and replace purely
image-based diagnosis, particularly when parametric im-
aging information is shown to increase specificity of
tracer accumulation by better separating cancerous from
in-active or inflammatory tissues.
Not all modalities provide equal access on quantita-
tive information in general, or to similar measure-
ments and parameters, which is why it is often key
for a disease as complex as cancer to consider them
in combination rather than on their own. For mor-
phological modalities, physical measurements can re-
late to the estimated size (e.g., RECIST or WHO
criteria [217, 218], in addition to volume), to the
shape of a given lesion (e.g., tortuosity, sphericity,
spiculation, etc. [219, 220]), or to structural character-
istics as interpreted through imaging (e.g., stereology,
BMD, HU in CT; DWI, ADC, DTI in MR; elastogra-
phy in MR and US; histogram and “texture” in all
modalities), all of which require the accurate segmen-
tation of the structures of interest. For functional mo-
dalities or protocols, physiological, metabolic and
functional characteristics can be extracted, such as re-
spiratory and cardiac motion, dynamic uptake of CT,
MR and radioactive tracers or binding of US contrast
agents. In the case of PET, individualised metabolic
surrogates, such as semi-quantitative SUV [221, 222]
or PERCIST [223], can be used, but a truly quantita-
tive approach, such as bona-fide pharmaco-kinetic
modelling, which is now re-emerging in clinical set-
tings, will be preferred as it provides much more re-
fined information about the actual inner workings or
response of the tissues of interest [224]. Here, lever-
aging increased volume sensitivities from extended
axial FOV coverage will be of the essence for robust
quantification even in early-phase, low-count imaging
situations shortly after tracer injection, or during
follow-up imaging after several half-lives of the
injected radioisotopes. Of special note about RECIST
and similar metrics that have been primarily devel-
oped for/through large clinical trials, while related
progression criteria can thus be considered as relevant
to and reasonably validated for large cohorts, they
may not necessarily be as meaningful for individual
patients and pathologies or consistently applied every-
where, and there are still ongoing debates about their
optimal use [225–229].
Naturally, standardized imaging pipelines are required
to ensure that any differences in measured quantitative
value are due to a real functional or morphological
change rather than a variation in the imaging process it-
self; this is irrespective of origin of biomarkers that can
be extracted from either morphological modalities or
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functional modalities. Examples of this standardization
process do not only include adherence to high standards
of quality control to ensure a repeatable and accurate
imaging system performance, but also requires a consist-
ent patient management workflow and robust image
analysis tools to extract quantitative biomarker informa-
tion. In multi-centre trials, this process further extends
to harmonizing differences between imaging platforms
while frequently relying on contract research organiza-
tions (CROs) to standardize the imaging protocols and
data analyses.
The recently formulated term of Radiomics now en-
compasses most extraction - and often combination - of
features that initially evolved organically for every mo-
dality and are mathematically derived from the digital
images at hand [230]. Even before the term Radiomics
was coined, the underlying assumption for extracting
such features was that, either on their own or in com-
bination with other data, they might be suitable surro-
gates for underlying biological, physiological or
morphological characteristics of particular relevance. Be-
cause such approaches tend to be very sensitive to the
initial data selection process, some of the main limits to
their clinical validation and deployment lies in the vari-
ability of source data (e.g., across centres or vendors)
and the complexity of identifying regions-of-interest in a
robust, consistent and accurate manner. With the advent
of better ways to harmonise and extract data, and also of
more advanced segmentation techniques informed by
statistical atlases and ML techniques, these approaches
should become easier to use and more reliable, thus,
opening the door to proper validation and eventually
broad clinical implementation. At any rate, the main aim
of quantitative approaches is to develop and identify ro-
bust imaging biomarkers that can be further combined
into so-called signatures/fingerprints for diagnosing and
characterizing disease as early as possible, and ideally
without requiring invasive tissue sampling via biopsies
or resections. These biomarkers will then be used for dy-
namically tailoring therapy regimen and assessing re-
sponse. However, combining various parameters into a
single signature may hide individual contributions, and
complex tentative Radiomics signatures should always
be carefully assessed [231], with negative results also be-
ing of relevance [232].
Artificial intelligence
Because of the high-dimensionality of multi-modality im-
aging data – either the source images or the parametric-
ally derived information – and of their cross-disciplinary
diversity, their meaningful and actionable analysis and in-
terpretation will increasingly rely on the assistance of
computers and advanced algorithms. Accordingly,
Machine Learning (ML) and associated Artificial
Intelligence (AI) approaches are becoming increasingly
ubiquitous in the medical imaging domain, from instru-
ment design and characterization, to acquisition, correc-
tions [233–235] and reconstructions.
While the potential of such approaches has already been
demonstrated in various scenarios [236], one should still
remain cautious about how the underlying models were
trained, and especially whether the data used at the train-
ing stage might have introduced some bias into the
models [237, 238]. To minimize such biases in either
population, pathology or even interpretation, proper ML/
AI training tends to require a high number of highly di-
verse (and high-quality) data in order to cover all possibil-
ities the algorithm may have to deal with, but such
numbers and diversity are rarely achievable in practice for
medical imaging, and especially so for rarer complex cases
that may thus be of most interest for these approaches. As
a way to mitigate this inherent limitation, synthetic data
can be created from existing ones in order to expand vir-
tually the learning space, but, again, some bias might be
introduced by how the simulation model is configured.
Another more versatile mitigation strategy, therefore, is to
ensure that any results obtained through ML/AI will be
fully explainable and come with a confidence score for a
human operator to assess.
The ultimate goal is personalized precision medicine
that is individually tailored to the patient and condition
at hand, as determined by in-vivo biomarkers derived
from imaging in combination with other information
(e.g., genomics, circulating tumour cells, etc.). While
therapies will be applied to real patients, in-vivo imaging
and derived information will be key to informing a vir-
tual – in-silico – model of the patient and their patholo-
gies down to the molecular level, on which a virtual
therapy regimen can then be devised and refined prior
to its real-life deployment.
Visualization
With ever more high-dimensional data and advanced ana-
lysis thereof comes the requirement to develop
visualization paradigms able to convey the most significant
information to human operators in a clear and unambigu-
ous fashion. Through ad-hoc data reduction techniques
and highly interactive systems incorporating multi-
dimensional input devices, this can be achieved through
standard means such as traditional 2D and 3D displays.
The increasing numbers of modalities and complexity of
information, as derived from both imaging and non-
imaging biomarkers and data [5], to be merged together
for a meaningful and actionable representation may still
eventually require other approaches, likely derived from
other areas, such as games or virtual reality, for more ad-
vanced visualization and interaction paradigms also
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relying on various senses and actuators (e.g., haptics,
sound, eye tracking, brain-computer interfaces, etc.). A
special case is for planning and guidance during interven-
tional or surgical procedures, where augmented and vir-
tual reality approaches will need to be implemented as
un-obstructively as possible to assist with both navigation
and delivery. Such approaches will also benefit from/to ro-
botic devices, from mere assistants to semi-autonomous
machines.
Need for training
With new, more capable and complex machines and ap-
proaches comes the need to train users so that they can
make the most of the added potential and also ensure
that expanded capabilities are used with a full under-
standing of their strengths and limitations [239]. New
medical school curriculuma already include some mater-
ial pertaining to advanced techniques and technology,
and conversion degrees (i.e., programmes providing for-
mal training in a separate discipline than one’s core de-
gree) will likely come up to complement the main
medical courses with imaging (incl. Modalities and ad-
vanced visualization), ML/AI, software engineering,
medical physics, etc. similarly to how disciplines, such
are biostatistics are currently taught to medical practi-
tioners (physicians, radiographer, technologists, physi-
cists, etc.) who want/need to expand their grasp of
disciplines relevant to their clinical work or research in-
terests [240].
Conclusions
Non-invasive imaging is an integral part of patient man-
agement, particularly in oncology. A range of imaging
modalities provides a wealth of information encompass-
ing anatomical, functional and molecular data. Imaging
modalities are also combined for so-called hybrid im-
aging concepts if the combination is made of comple-
mentary imaging methods and if, as in many cases, such
hybrid imaging systems are both feasible and cost effect-
ive. Together, technologies and methodologies advance
quickly thanks to innovations by clinical researchers and
users as well as equipment manufacturers. General
trends in these advances include attempts to make im-
aging faster, more accurate and more amenable to pa-
tients. Lately, the use of ancillary machine learning
approaches and artificial intelligence has become the
focus of attention so as to reduce image distortions, re-
duce patient exposure or examination time, and last but
not least, to assist the clinical readers with supplemen-
tary decision support systems. In order to keep pace
with the systemic advances of imaging, clinical users and
readers are required to continuously update their know-
ledge and understanding. Finally, non-invasive imaging
does provide only a snapshot of the patient, while other
biomarkers, including omics, may add to the breadth of
diagnostic information. Therefore, a closer integration of
imaging and non-imaging methods is expected over the
years to come as one of the key components of truly
personalized medicine.
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